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Abstract 
 
Several studies have shown that neurotrophins and neuropeptides contribute to 
epileptogenesis but their impact on idiopathic generalized epilepsies is not yet 
elucidated. Generalized absence seizures are a specific type of epilepsy occurring 
predominantly in children. Sudden onset and termination of typical bilaterally 
synchronous 3Hz spike-and-wave discharges on the electroencephalogram and a 
brief impairment of consciousness with interruption of ongoing activity are hallmarks 
of this disease. New classes of absence drugs designed to block the process of 
epileptogenesis are needed because known treatments are not effective in all 
patients and a broad spectrum of adverse reactions has been described. Drug 
screening is hindered because the molecular mechanisms underlying generalized 
absence seizures are still not completely clarified. Genetic Absence Epilepsy Rats 
from Strasbourg (GAERS) used in this study are a valid animal model that 
spontaneously displays many of the characteristics of human absence epilepsy. 
 
The aim of this thesis was to define the potential role of neurotrophins and 
neuropeptides in generalized absence seizures with special regard to expression 
differences between GAERS and control animals, changes during maturation and 
region-specific expression alterations. Additionally, the consequences of their 
application on seizure initiation and termination were studied. 
 
Brain-derived neurotrophic factor (BDNF) is ubiquitously expressed in brain and 
involved in several physiologic and pathologic processes including epilepsy. 
Glutamate release is enhanced, whereas inhibitory transmission is diminished by 
BDNF. Its signaling pathway is significantly impaired in adult GAERS after the onset 
of absence seizures due to reduced expression of BDNF receptors and transcription 
factors. Nevertheless, intracerebroventricular injection of BDNF significantly reduces 
the occurrence of spike-and-wave discharges in adult GAERS. 
 
Neuropeptides are cofactors of the classical neurotransmitters and therefore 
important modulators of neuronal excitability. Expression of the anticonvulsant agent 
neuropeptide Y (NPY) is directly influenced by BDNF. The density of NPY-expressing 
cells is clearly increased in GAERS compared to control animals. Additionally, the 
onset of absence seizures in adult GAERS is associated with a drastic decrease of 
brain NPY content. Application of NPY and agonists to its receptors efficiently 
suppresses spike-and-wave discharges in adult GAERS. In contrast, absences are 
evoked in juvenile GAERS following treatment with specific NPY receptor 
antagonists.   
 
In conclusion, this thesis demonstrates that BDNF as well as NPY exert potent anti-
absence effects in adult GAERS. BDNF and NPY both represent accessible systems 
to intervene in brain excitability and thus provide new molecular targets for 
efficacious treatments against generalized absence epilepsy. 
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Zusammenfassung 
 
Wie bereits in mehreren Studien gezeigt wurde, sind Neurotrophine und 
Neuropeptide in die Epileptogenese involviert, wobei ihre Wirkung bei idiopathischen 
generalisierten Epilepsien noch nicht geklärt ist. Generalisierte Absenzen sind eine 
spezifische Art von Epilepsie, die vor allem im Kindesalter auftritt. Besondere 
Merkmale sind das plötzliche Auftreten und Verschwinden von typischen 
Anfallsmustern im Elektroenzephalogramm mit einer Frequenz von 3Hz, die beide 
Gehirnhemisphären synchron betreffen, sowie eine kurze Bewusstseinsstörung, bei 
der laufende Aktivitäten unterbrochen werden. Die bisher bekannten Therapien sind 
nicht für alle Patienten wirksam und weisen ein breites Spektrum an unerwünschten 
Nebenwirkungen auf. Deshalb werden dringend neue Medikamente benötigt, welche 
die Entstehung der Epilepsie hemmen. Die Entwicklung von neuen 
Therapieansätzen wird jedoch dadurch erschwert, dass die molekularen 
Mechanismen, welche der Krankheit zu Grunde liegen, noch nicht vollständig 
bekannt sind.  
 
Ziel dieser Arbeit war es, den möglichen Einfluss von Neurotrophinen und 
Neuropeptiden in der Entstehung von Absenzen aufzuklären. Dafür wurden GAERS-
Ratten verwendet, die zahlreiche charakteristische Eigenschaften der menschlichen 
Absenzen aufweisen. Besondere Aufmerksamkeit wurde dabei auf 
Expressionsunterschiede zwischen GAERS und Kontrolltieren und Änderungen 
während der Entwicklung gelegt. Zusätzlich wurde die Auswirkung von 
Neurotrophinen und Neuropeptiden auf das Auftreten und Verschwinden der Anfälle 
untersucht. 
 
Das Neurotrophin Brain-Derived Neurotrophic Factor (BDNF) ist im Gehirn weit 
verbreitet und spielt bei physiologischen wie auch pathologischen Prozessen so auch 
bei der Epilepsie eine wichtige Rolle. BDNF fördert die Ausschüttung von erregenden 
Neurotransmittersubstanzen wie Glutamat, während die hemmende 
Signalübermittlung abgeschwächt wird. Unsere Untersuchungen weisen darauf hin, 
dass die Signalkaskade von BDNF in adulten GAERS nach dem ersten Auftreten von 
Absenzen merklich gestört ist, da die Synthese von Rezeptoren und 
Transkriptionsfaktoren von BDNF reduziert ist. Funktionell bedeutsam ist, dass die 
intrazerebroventrikuläre Injektion von BDNF eine signifikante Verminderung der 
Absenzen bewirkt. 
 
Neuropeptide sind Kofaktoren von klassischen Neurotransmittern und deshalb 
wichtige Modulatoren der neuronalen Erregbarkeit. Die Synthese des antikonvulsiven 
Neuropeptids NPY wird direkt durch BDNF reguliert. Die Dichte an NPY-
exprimierenden Zellen ist in GAERS stark erhöht im Vergleich zu Kontrolltieren. 
Zusätzlich wird das erstmalige Auftreten von Absenzen von einem deutlichen Abfall 
der NPY Konzentration in verschiedenen Hirnregionen begleitet. Darüber hinaus 
unterdrückt die exogene Gabe von NPY und NPY-Rezeptor Agonisten das Auftreten 
von Absenzen in adulten GAERS. Antagonisten gegen NPY-Rezeptoren können 
hingegen Anfälle in jungen GAERS auslösen. 
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Zusammenfassend kann gesagt werden, dass BDNF wie auch NPY stark gegen 
Absenzen in adulten GAERS wirksam sind. Beide Substanzen bieten gut 
zugängliche Systeme, um die Erregbarkeit des Gehirns zu beeinflussen, und können 
deshalb als neue molekulare Angriffsorte für therapeutische Interventionen gegen 
Absenzen verwendet werden.    
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1  Introduction 
 
1.1 Epilepsy 
Epilepsy is characterized by excessive and/or hypersynchronous, usually self-limited 
activity of neurons in the brain. Causes might be enhanced connectivity or excitatory 
transmission, a failure of inhibitory mechanisms or changes in intrinsic neuronal 
properties (Duncan, Sander et al. 2006). The International League Against Epilepsy 
(ILAE 2009) developed a standardized classification and terminology for epileptic 
seizures which distinguishes between focal and generalized seizures and status 
epilepticus (table 1). Focal seizures are initially activated in only a part of one 
cerebral hemisphere resulting in involuntary movement, unusual sensations or 
attention and behavioral changes. They can spread by recruitment of other brain 
areas. In contrast, in generalized forms of epilepsy the abnormal electrical activity 
encompasses both hemispheres of the brain leading to a complete loss of 
consciousness (Manning, Richards et al. 2003). Two major forms belong to 
generalized seizures: absence seizures (formerly known as petit mal) and tonic-
clonic seizures (grand mal) which occur in two phases. In the first tonic phase 
muscles stiffen, the body grows rigid and the patient loses consciousness and falls. 
Afterwards, jerking and twitching of body extremities occur in the clonic phase. A 
second tonic phase may follow. Consciousness returns slowly and the patient is often 
confused and disoriented. Status epilepticus is a state of recurrent seizures during 
which consciousness does not return. It is a potentially life-threatening event which 
can lead to severe brain damage (according to ILAE, 1981; 1989; Engel 2001). 
 
Table 1: Differentiation of epileptic seizure types with the focus on absence 
seizures (adapted from ILAE 2009) 
Epileptic seizure type   
I  Self-limited seizure types 
 A Focal seizures 
 B Generalized seizures 
  i Typical absence seizures 
  ii Atypical absence seizures 
  iii Myoclonic absence seizures 
II Continuous seizure types 
A Focal status epilepticus  
B Generalized status epilepticus 
  iv Absence status epilepticus 
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1.1.1  Absence epilepsy 
According to ILAE, absence seizures belong to idiopathic generalized epilepsies 
(Avoli, Rogawski et al. 2001). They can be divided in four subtypes (table 1): (i) 
typical absences, (ii) atypical absence seizures, (iii) myoclonic absence seizures and 
(iv) absence status epilepticus (Panayiotopoulos 1999b; ILAE 2009). 
In table 1, the classification depends on the epileptic seizure type each of which 
represents a unique pathophysiological mechanism. It is a diagnostic entity with 
etiologic, therapeutic and prognostic implications. 
Another possibility for classification is the epilepsy syndrome. It is a complex of 
different signs and symptoms that define a unique epilepsy condition involving more 
than just the seizure type (Engel 2001). Three epileptic syndromes belong to typical 
absences, namely childhood absence epilepsy, juvenile absence epilepsy and 
juvenile myoclonic epilepsy (table 2, Panayiotopoulos 1999a). 
 
Table 2: Summary of the most important epilepsy syndromes mentioned in this 
thesis (adapted from ILAE, Engel 2001) 
Epilepsy syndromes 
? Typical absence seizures 
o Childhood absence epilepsy 
o Idiopathic generalized epilepsies with variable phenotypes 
A Juvenile absence epilepsy 
 B Juvenile myoclonic epilepsy 
? Myoclonic absence epilepsy 
? Familial temporal lobe epilepsies 
? Conditions with epileptic seizures that do not require a diagnosis of epilepsy 
 A Febrile seizures 
 
1.1.1.1 Pathophysiology and epidemiology of absence seizures 
Typical absence epilepsy consists of brief generalized epileptic seizures lasting up 
to 20 seconds with an abrupt onset and termination without a preceding aura 
(Panayiotopoulos 1999b). They are characterized by a sudden, brief impairment of 
consciousness and 3-4Hz bilaterally synchronous spike-and-wave discharges 
(SWDs) which can be recorded on the electroencephalogram (EEG, figure 1, 
according to ILAE 2009). An interhemispheric synchronization is required for the 
generalized nature which can be observed at seizure onset and throughout the whole 
discharge (Avoli, Rogawski et al. 2001). Patients interrupt ongoing activities, stare 
while their eyes are open, remain unresponsive and suddenly resume the pre-
absence activity. Absence seizures occur very frequent, about ten to hundred times 
each day. As they occur mainly in children and are associated with a fixed, vacant 
stare, they are often mistaken for day-dreaming or remain unnoticed 
(Panayiotopoulos 1999b; Crunelli and Leresche 2002; Manning, Richards et al. 
2003). 
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Figure 1: EEG of a child with typical absence seizures. Typical 3Hz spike-and-
wave discharges are recorded for 9 seconds. Absence epilepsy starts and ends 
abruptly. Green vertical lines mark each second on the time scale (kindly provided by 
Prof. J. Lütschg, UKBB, Basel). 
 
Absences are often associated with other symptoms such as mild clonic jerks, atonic 
components, tonic muscular contractions, automatisms (as e.g. lip smacking or 
licking, swallowing, fumbling with clothes, aimless walking), visual hallucinations and 
autonomic disturbances. Typical absences occur spontaneously but may be 
influenced by different factors such as anger, sorrow, fear, surprise, embarrassment, 
lack of interest, release of attention, meal- or school-time, awakening and metabolic 
factors as hypoglycemia (Loiseau 1992). For differential diagnosis, patients are 
asked to hyperventilate for three minutes while standing and count the breaths (for 
detection of impairment of consciousness) as absence seizures occur in more than 
90% of the patients during hyperventilation (Panayiotopoulos 1999b).  
 
Childhood absence epilepsy, also called pyknolepsy, occurs with an incidence of 1 
in 1’000. Seizures start usually before the age of 10 years and peak at 5-6 years with 
higher prevalence in girls. In spite of the fact that pyknolepsy occurs very frequently 
during the day, it is the most innocuous type of generalized seizures because motor 
and autonomic manifestations are rare. The hallmark is a sudden onset and 
interruption of ongoing activities, often accompanied by a blank stare. An oligogenic 
or digenic model for inheritance is suggested. Patients are usually unaware of the 
seizure and respond well to medical treatment. Seizure remission occurs in more 
than 90% before the age of 12 years. Drug treatment can be withdrawn gradually 
after a seizure free time of 2-3 years (Snead 1995; Panayiotopoulos 1999a; Avoli, 
Rogawski et al. 2001; Manning, Richards et al. 2003). Factors for less favorable 
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prognosis are early or late onset (<4 or >9 years), initial drug resistance and 
photosensitivity. Persistence of seizures results usually in generalized tonic-clonic 
convulsions (Guerrini 2006).  
 
Onset of juvenile absence epilepsy which is often accompanied by generalized 
tonic-clonic seizures and random myoclonic jerks occurs after the age of 10 years 
with a peak between 10 and 12 years. This type of seizures occurs with an incidence 
of 1 in 3’000 and is much more sporadic during the day than childhood absences. 
Girls and boys are equally affected. Frequency of SWDs can be faster (3.5-4.5Hz) 
than in childhood absences (Wolf 1993; Panayiotopoulos 1999a; Avoli, Rogawski et 
al. 2001). 
 
Juvenile myoclonic epilepsy which starts in mid-teens is characterized by 
myoclonic jerks after awakening and generalized tonic-clonic seizures. Only one third 
of patients exhibit absences which are usually mild and without concurrent myoclonic 
jerks or automatisms. Both sexes are equally affected from juvenile myoclonic 
epilepsy which occurs in one out of 2’000 children (Panayiotopoulos 1999a; Avoli, 
Rogawski et al. 2001).  
 
Atypical absences occur in the context of mainly severe symptomatic or cryptogenic 
epilepsies. Affected children have learning difficulties and suffer from frequent other 
types of seizures such as atonic, tonic and myoclonic seizures (Panayiotopoulos 
1999a). SWDs are slower with a frequency between 1.5-2.5Hz and without precise 
beginning or ending. Additionally, eyelid clonia and automatisms may occur. The 
incidence of atypical absences varies from a few per day to nearly continuous. The 
lack of rhythmicity of the discharges is a remarkable feature of atypical absences 
which start in school age (Dulac 1999). 
 
Patients suffering from myoclonic absence seizures have learning difficulties and a 
poor prognosis. Absence seizures are associated with bilateral rhythmic myoclonic 
jerks of severe intensity involving muscles of the shoulders, arms and legs. Facial 
muscles are less affected. The loss of consciousness may be complete or only 
partial. Seizure onset is around 7 years with a male preponderance. Hyperventilation, 
awakening and intermittent light can trigger a seizure (Tassinari, Rubboli et al. 1999; 
Panayiotopoulos 1999a). 
 
Prolonged absence seizures lasting more than half an hour up to several days are 
called absence status epilepticus. It occurs in 10-30% of idiopathic generalized 
epilepsies with absences but not in the pure form of childhood absence epilepsy. 
Symptoms occur continuously or repetitively and last until the cessation of the status 
(Panayiotopoulos 1999b). Cardinal symptoms are clouding of consciousness, slow 
mind, withdrawal, slowness of responses and confusion often accompanied by 
eyelid, peri-oral or limb jerks. Verbal functioning is relatively well preserved and 
movement and coordination are intact. Absence status epilepticus is often not 
recognized or misdiagnosed (Agathonikou, Panayiotopoulos et al. 1998). 
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1.1.1.2 Molecular mechanisms underlying absence seizures 
In contrast to generalized or focal convulsive seizures which are characterized by an 
excess of excitatory activity, absence epilepsy is related to a predominance of 
inhibition. 
Seizure activity originates in the peri-oral region of the somatosensory cortex as 
shown for Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats (Meeren, Pijn et al. 2002) and 
Genetic Absence Epilepsy Rats from Strasbourg (GAERS, Polack, Guillemain et al. 
2007) and generalizes rapidly over the cortex (figure 2). Blockade of action potentials 
by tetrodotoxin in somatosensory cortex prevents the occurrence of local and distant 
SWDs (Polack, Mahon et al. 2009). The fact that injection of ethosuximide, a calcium 
channel blocking agent, into thalamic nuclei is not sufficient for a full anti-absence 
effect (Richards, Manning et al. 2003), whereas targeting the peri-oral region of the 
primary somatosensory cortex produces an immediate cessation of seizure activity 
(Manning, Richards et al. 2004) gives another indication for the focal origin of SWDs 
in the cortex. Secondly, oscillation is initiated within thalamocortical loops 
transforming the spike into spike-wave activity. In these first cycles of the seizure, the 
cortex drives the thalamus. Thereafter, rhythmic discharges are amplified and 
maintained by the interplay between cortex and thalamus alternatively leading and 
lagging in an unpredictable way (Meeren, van Luijtelaar et al. 2005). Neither cortex 
nor thalamus alone is able to sustain the discharges indicating that both structures 
are involved in the generation of SWDs (figure 2). 
 
 
 
 
Figure 2: Cortical focus of absence epilepsy. Seizures arise from a consistent 
focus within the peri-oral region of the somatosensory cortex (circle). Epileptic activity 
generalizes rapidly over the cortex and thereafter to the thalamocortical network. 
Then, thalamus and cortex drive each other and amplify and sustain the discharges 
(part of illustration from Meeren, van Luijtelaar et al. 2005).  
  
The thalamus modulates the flow of external information to the cortex by shifting 
between an oscillatory and tonic firing mode. Desynchronized EEG caused by tonic 
firing allows faithful signal transmission from the external environment to the cortex 
leading to an alert behavioral state. On the other hand, the threshold for excitatory 
postsynaptic potentials (EPSPs) is raised when thalamic neurons burst in an 
oscillatory, rhythmic firing mode leading to diminished signal transmission to the 
cortex and reduced consciousness (Snead 1995). Three neuronal classes exist in the 
thalamus: (i) Thalamocortical neurons projecting to the cortex are glutamatergic. (ii) 
Inhibitory neurons from the nucleus reticularis thalami (nRT) contain γ-amino-butyric 
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acid (GABA) and project back to thalamocortical neurons. (iii) Local GABAergic 
interneurons inhibit thalamic transmission (figure 3). GABAergic neurons of the nRT 
have the intrinsic ability to shift between the two firing modes and to impose their 
behavior on thalamocortical circuitry. Most parts of the thalamus are covered by the 
neuronal sheet of the nRT (Steriade 2001). Its neurons receive excitatory, 
glutamatergic input from thalamocortical as well as corticothalamic fibers. 
Additionally, nRT diffusely projects to virtually all dorsal thalamic territories (Steriade 
2005). Therefore, nRT is uniquely situated to insure a wide synchronization of 
oscillations and to influence the flow of information between thalamus and cortex. 
Generalized absence seizures represent a perturbation of the rhythmicity in favor of 
the oscillatory firing mode (Steriade and Contreras 1995) explaining the absence of 
incoming signals from the external world and the unconsciousness (Steriade 2001; 
Slaght, Leresche et al. 2002). 
Firing of nRT units drastically changes with the appearance of SWDs in the EEG. 
Prolonged, high-frequency action potential bursts occur in the nRT at the same 
frequency as SWDs in the EEG as a response to cortical stimulation (Steriade 2001).  
Glutamate-mediated EPSPs from the cortex activate neurons in the nRT which in 
turn release GABA. Activation of GABAB receptors leads to hyperpolarization which 
in turn converts low-threshold T-type Ca2+ channels in an activated state. Activation 
of these channels is the cellular event underlying the shift between oscillatory and 
firing mode (Slaght, Leresche et al. 2002). Hyperpolarization of the membrane 
potential in nRT to -75mV leads to spontaneous oscillations whereas depolarization 
to -55mV favors the tonic firing mode (Pape, Meuth et al. 2005). The following Ca2+-
mediated burst discharge facilitates the release of excitatory amino acids leading to 
EPSPs in the cortex. This process leads to another depolarization and the cycle 
repeats itself (Manning, Richards et al. 2003). Repolarization of thalamocortical 
neurons occurs by activation of voltage-gated K+ channels (Feuerstein 2001). Spikes 
represent EPSPs, whereas slow waves are associated with inhibitory postsynaptic 
potentials (IPSPs, Giaretta, Avoli et al. 1987). In conclusion, the typical synchronized 
3Hz SWDs in generalized absence seizures are generated by an overshooting 
inhibition of thalamic neurons (figure 3). 
Sudden rhythmic membrane depolarizations temporally correlated with SWDs are 
also seen in cortico-striatal neurons. An abrupt membrane hyperpolarization in these 
neurons is correlated with the start of SWDs and its removal coincides with the end 
of SWDs (Panayiotopoulos 1999b). 
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Figure 3: Thalamocortical network influencing absence seizures. Descending 
corticothalamic projections (CT) activate neurons of the nucleus reticularis thalami 
(nRT), thalamic interneurons (IN) and thalamocortical (TC) neurons via excitatory 
glutamatergic transmission (blue). Thalamocortical neurons project back to cortical 
structures amplifying the excitation by activating other corticothalamic neurons. 
Additionally, inhibitory interneurons in thalamus and cortex as well as neurons of the 
nRT are activated (green). Projections form the nRT to other thalamic structures as 
well as interneurons block excessive excitation via inhibitory GABAergic transmission 
(red). 
 
1.1.1.3 Medical treatment of absence seizures 
Generalized absence seizures are completely different from other type of seizures 
and therefore pharmacologically unique. The common antiepileptic drugs 
carbamazepine, vigabatrin and tiagabine are contradicted in absence seizures 
because they can induce seizures or even absence status epilepticus, whereas 
phenytoin, phenobarbitone and gabapentin are ineffective (Snead, Depaulis et al. 
1999). First choice therapies of absence seizures are valproate (Convulex®, Orfiril®, 
Depakine®), ethosuximide (Petinimid®), mesuximide (Petinutin®) and 
benzodiazepines (for review see Feuerstein 2001; Manning, Richards et al. 2003). 
Ethosuximide blocks low-threshold calcium currents via direct action on T-type Ca2+ 
channels and decreases persistent Na+ and sustained Ca2+-activated K+ currents 
(Broicher, Seidenbecher et al. 2007). Its direct application on the peri-oral regions of 
the primary somatosensory cortex exerts most efficacious inhibition of absence 
seizures (Manning, Richards et al. 2004). Intraperitoneal application of ethosuximide 
produces an immediate reduction of SWDs and a significant decrease in GABA 
levels in the primary motor cortex of GAERS (Terzioglu, Aypak et al. 2006). 
Mesuximide also blocks voltage-dependent T-type Ca2+ channels. Although any drug 
that facilitates GABA actions exacerbates absence seizures, valproate and 
benzodiazepines are commonly used for treatment. The mode of action of valproate 
on SWD suppression is not clear. Valproate increases GABA concentration by 
stimulating its synthesis and inhibiting its metabolism. The predominant action of 
valproate seems to involve inhibition of voltage-dependent Na+ and T-type Ca2+ 
channels (Broicher, Seidenbecher et al. 2007). Valproate additionally controls 
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myoclonic jerks and generalized tonic-clonic seizures. Benzodiazepines are believed 
to selectively affect nRT by enhancing GABA-mediated inhibitory neurotransmission 
via GABAA receptors and suppressing the spread of seizure activity. Another 
possibility to treat absences is lamotrigine (Lamictal®), a drug that inhibits Na+ 
channels and reduces glutamate concentrations (Duncan, Sander et al. 2006). 
Typical absences are normally treated with only one drug titrated up to the maximum 
tolerated dose. Polytherapy is required in only a small percentage of cases with 
typical absence epilepsy whereas therapy of atypical absences is more complex 
(Panayiotopoulos 1999b). Polytherapy increases the possibility of poor compliance, 
drug interactions, teratogenicity and long-term toxic effects (Duncan, Sander et al. 
2006). Low doses of lamotrigine can be added to adequate doses of valproate in 
therapy-resistant patients. Other possibilities for the few remaining cases of 
treatment failure are acetazolamide (Diamox®) and benzodiazepines as clonazepam 
(Rivotril®). The latter is particularly effective in absences with myoclonic components 
(Dulac 1999). Atypical absences can also be treated with felbamate (Taloxa®), 
steroids and ketogenic diet (Panayiotopoulos 1999b). Intravenous diazepam 
(Valium®) or valproate or buccal application of midazolam (Dormicum®) are first 
choice treatments for absence status epilepticus (Panayiotopoulos 1999a). 
Despite several treatment possibilities 10 to 20% of patients may not achieve control 
of seizures. Valproate is not desirable in women because of different side effects 
such as teratogenicity, weight gain and polycystic ovarian syndrome. Efficacy and 
adverse reactions have to be carefully balanced as treatment often last the whole life 
(Richards, Lemos et al. 1995). The need for new classes of absence drugs is urgent, 
because known treatments are not effective in all cases of absence epilepsy and a 
broad spectrum of side effects has been described (Koutroumanidis, Hennessy et al. 
1999; Jeha, Morris et al. 2006). 
 
1.1.2  Febrile seizures 
Febrile seizures are the most common form of childhood seizures affecting 2-5% of 
all children and occurring in about 30% of patients with childhood absence epilepsy 
(Marini, Harkin et al. 2003). Children between 6 months and 5 years with a peak at 
18-22 months are affected. Febrile seizures can be divided in simple and complex 
seizures. 75% of first febrile convulsions are simple with tonic-clonic seizures, 
duration less than 15 minutes and no recurrence within one day. Complex seizures 
are mainly focal with longer duration and a cluster of two or more convulsions during 
24 hours. The earlier the age of onset, the greater is the risk of recurrence. Three 
features mainly underlie the genesis of febrile seizures: immature brain, fever and 
genetic predisposition. Increasing myelination, “dying back” of excessive neurons 
and augmentation of synaptic complexity occur in this time frame of brain maturation. 
Causes for fever may vary from different infections to noninfectious illnesses. A 
polygenetic inheritance is suggested for this disease. In a family study, febrile 
seizures seem to have an autosomal dominant mode of inheritance with 75% 
penetrance (Dube, Brunson et al. 2005). GABAA receptor γ2 subunit missense 
mutation (R43Q) was linked with childhood absence epilepsy and febrile seizures. 
Reduced cell surface expression of GABAA receptor results in increased neuronal 
excitability and epilepsy (Marini, Harkin et al. 2003). A family study showed that 64% 
9 
 
of all people with this mutation had febrile seizures, 21% childhood absence epilepsy 
and 15% a generalized epilepsy with febrile seizures plus phenotype (Doose 1998).  
Febrile seizures are usually brief and self-limited. A short febrile convulsion does not 
damage the brain. Prolonged convulsions are treated with intravenous or rectal 
anticonvulsants such as diazepam, midazolam or lorazepam. Rigorous use of 
antipyretic medication does not prevent febrile seizures. Although prophylactic daily 
therapy is not recommended, phenobarbital and valproate reduce the recurrence, but 
the potential side effects of drugs outweigh the benefits (for review see Arzimanoglou 
2004). Long-lasting febrile convulsions (>1h) can lead to cognitive and motor 
developmental deficits and patients can later develop complex partial seizures and 
therapy-resistant epilepsies (Danober, Deransart et al. 1998). 
 
1.1.3  Focal seizures 
Focal seizures can be divided in complex and simple seizures depending on whether 
consciousness is affected or not. Seizures with a focal beginning can also 
secondarily generalize. Complex partial seizures usually arise from the limbic lobe 
including amygdala, hippocampus and less often from the temporal neocortex. 
Seizures are often accompanied by psychic, sensory and motor phenomena. The 
most frequent type of focal epilepsies with a high percentage of pharmacoresistant 
patients is temporal lobe epilepsy (TLE). Neuropathological properties as severe 
neurodegeneration in the hippocampus or related brain areas are characteristic for 
TLE which can be initiated by prolonged febrile convulsions in early life or by a status 
epilepticus. 40-50% of patients with TLE are not seizure free despite an adequate 
pharmacotherapy (Sperk 2006). 
 
1.1.4  Animal models for focal and generalized tonic-clonic 
seizures 
Animal models mimicking complex partial or generalized tonic-clonic seizures are 
frequently used to investigate epilepsy mechanisms (Sarkisian 2001). 
 
1.1.4.1  Kindling model for brain plasticity 
Kindling is a model to induce long-term plastic changes in brain excitability. Shortly, 
bipolar stimulating electrodes are implanted in amygdala or hippocampus. Then, 
daily electrical stimuli were applied for several days until electrical afterdischarges 
are observed which become progressively more complex and prolonged with each 
kindling stimulus. Spontaneous epileptic seizures in the absence of electrical stimuli 
occur after continued kindling for a few weeks (Fisher 1989). Kindled dentate gyrus 
has an increased efficiency to release glutamate (Rodi, Mazzuferi et al. 2003). The 
development of seizures can be divided into 5 different stages using the Racine 
scale: 1. mouth and facial movements; 2. head nodding; 3. forelimb clonus; 4. 
rearing; 5. falling. Full motor seizures with loss of postural control are referred to 
stage 5. Stages 4 and 5 are considered as models for secondarily generalized 
complex partial seizures (Racine 1972). Kindling leads to mossy fiber sprouting in the 
dentate gyrus and cell death in hilus, hippocampal cornu ammonis (CA) 3 and CA1 
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pyramidal neurons of hippocampus (Sarkisian 2001). This model is especially useful 
for investigations of changes that occur in brain over time. Seizures and the 
disposition of brain regions to develop them can be investigated (Fisher 1989). 
 
1.1.4.2  Kainic acid-induced complex partial seizures 
Kainic acid is a glutamate analog that can be systemically or intracerebrally injected 
into animals and rapidly produces acute seizures. In low doses, kainic acid induces 
complex motor activity and sometimes generalized tonic-clonic activity (Fisher 1989). 
Higher doses induce severe acute seizures with subsequent status epilepticus. After 
a quiescent period of several weeks spontaneous recurrent seizures develop. Kainic 
acid generates lesions similar to those observed in patients with temporal lobe 
sclerosis. It is able to produce selective lesions of cell bodies in the brain, especially 
in hippocampus including loss of GABAergic interneurons in the dentate hilus and 
pyramidal cell death within CA3 and CA1 (Sarkisian 2001), while axons are 
preserved (Fisher 1989). Disadvantages of this model are the difficult control of 
status epilepticus, the unpredictable spontaneous seizures and the extensive neural 
damage (Morimoto, Fahnestock et al. 2004). 
 
1.1.4.3  Lithium-pilocarpine seizure model 
Pilocarpine is a muscarinic cholinergic agonist which produces rapidly acute seizures 
after systemic or intracerebral injection. Large doses evoke acute seizures that are 
accompanied by status epilepticus followed by a quiescent period of several weeks 
(Sarkisian 2001). Neuronal damage develops during this silent period affecting 
hippocampus, cortex, amygdala as well as thalamus (Andre, Dube et al. 2007). In 
detail, loss of GABAergic interneurons in the dentate hilus and pyramidal cell death 
are observed. Afterwards, spontaneous recurrent seizures develop (Sarkisian 2001). 
Pretreatment with lithium increases the susceptibility of rats to pilocarpine-induced 
seizures (Turski, Ikonomidou et al. 1989). 
 
1.1.4.4  Pentylenetetrazol-kindling 
Parenteral application of pentylenetetrazol, a systemic convulsant, primarily produces 
myoclonic jerks which may lead to generalized tonic-clonic seizures. 
Pentylenetetrazol decreases the potency of GABA-mediated inhibition thus leading to 
seizure generation (Fisher 1989). Repeated injections produce a type of chemical 
kindling that resembles electrical kindling. Given systemically at very low doses, it 
elicits absence-like seizures (Sarkisian 2001). 
 
1.1.4.5  Flurothyl model of epileptogenesis 
Flurothyl is a chemical inhalant that causes myoclonic jerks followed by severe tonic-
clonic convulsions (Sarkisian 2001). Application of the chemoconvulsant flurothyl on 
consecutive days each evoking a generalized seizure leads to a permanent and rapid 
reduction of seizure threshold and spreading of seizures in mice (Mhyre and 
Applegate 2003). 
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1.1.5  Drug-resistant epilepsies 
The percentage of pharmacoresistant patients remains stable between 20 and 25% 
despite the development of new anticonvulsant drugs (Jeha, Morris et al. 2006). 
Multiple pathogenetic mechanisms such as differences in seizure onset and 
progression or different individual sensitivity may underlie refractoriness. 40% of 
drug-resistant childhood epilepsies are caused by malformations of the cerebral 
cortex (Guerrini 2006). Intractable epilepsies are often associated with hippocampal 
sclerosis. Temporal lobectomy is an established treatment for patients with refractory 
focal epilepsy (Crunelli and Leresche 2002), a cost-effective procedure which carries 
a chance of 60-70% to make the patient seizure-free accompanied by improved 
quality of life (Duncan, Sander et al. 2006). Another non-pharmacological option to 
treat severe forms of drug-resistant epilepsy in pediatric practice is a ketogenic diet 
consisting of high fat (80%), low protein (15%) and very low carbohydrate (5%) 
amounts. Increased formation of ketone bodies which are structurally similar to 
GABA seems to be the efficacious mechanism of the diet (Kossoff 2004). 
Drug-intractable epilepsy is a major health problem, associated with morbidity and 
mortality and accounting for much of the economic burden of epilepsy (Regesta and 
Tanganelli 1999). 
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1.2  Genetic Absence Epilepsy Rats from 
Strasbourg (GAERS) 
Studies of the pathophysiological mechanisms of absence epilepsy cannot be 
conducted in humans due to ethical reasons as mainly children and adolescents are 
affected and the disease has only moderate consequences. Therefore, most 
information derives from studies in animal models (Vergnes, Marescaux et al. 1982). 
1.2.1  Characterization of GAERS 
Coincidentally, it was observed that normal adult Wistar rats display spontaneous 
synchronous paroxysmal bursts consisting of SWDs in the EEG (Danober, Deransart 
et al. 1998). These rats had then been selectively inbred over 37 generations 
resulting in two different strains: all animals of the first group exhibit SWDs (GAERS) 
and the others were all seizure-free (non-epileptic controls (NEC)). No SWDs are 
observed in GAERS younger than 30 days. Then, SWDs gradually occur and at the 
age of 3 months 100% of GAERS are affected (Vergnes, Marescaux et al. 1986). At 
first, discharges are rare, irregular and brief with a low frequency (5-7Hz) called short 
irregular spike-and-wave discharges (SISWDs, figure 4A). Thereafter, number, 
duration and frequency increase progressively possibly as a consequence of 
neurochemical modifications occurring during brain development (Vergnes, 
Marescaux et al. 1982). A maximum of SWDs which persist until death is reached 
around 4-6 months. Typical SWDs feature a frequency of 7-11Hz, durations between 
1-40s and spike amplitudes 2-6 times greater than background activity with an abrupt 
start and end on a normal EEG background (figure 4B). The average discharge lasts 
6±3.4s with an incidence of 1.3±0.4/min. Concomitant phenomena are behavioral 
immobility, staring, rhythmic twitching of the vibrissae and facial muscles resulting in 
a gradual lowering of the head. A sudden rise of the head to its previous position 
marks the end of discharges which are preferentially observed during quite 
wakefulness. When discharges occur during active states, movement is suddenly 
interrupted and activity resumes as soon as the discharge stops. SWDs are 
immediately interrupted by unexpected sensory stimulation, although responsiveness 
to mild sensory stimuli is abolished (Crunelli and Leresche 2002; Rudolf, Bihoreau et 
al. 2004). Spontaneous activity, exploration, feeding, social interactions, learning and 
sexual behaviors are not impaired in GAERS as compared to NEC. 
The transmission of seizures is polygenic and autosomal dominant as shown by 
Mendelian cross-breeding. A dominant gene is probably responsible for the epileptic 
phenotype and further genes modify duration and number of seizures (for review see 
Danober, Deransart et al. 1998; Rudolf, Bihoreau et al. 2004) 
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Figure 4: EEGs measured from juvenile and adult GAERS. A, juvenile GAERS 
display short irregular spike-and-wave discharges (SISWDs) with frequencies 
between 5 and 7Hz and short duration. B, typical 7Hz spike-and-wave discharges 
(SWDs) recorded from adult GAERS. 
 
1.2.2  Prospects and constraints of this animal model 
Convincing animal models for absence epilepsy should achieve the following criteria 
proposed by Snead et al. (1999): 
1. Bilaterally synchronous SWDs associated with behavioral arrest with or 
without head drop and nystagmus 
2. Reproducibility and predictability 
3. Ability to standardize and quantify 
4. Amelioration by ethosuximide, valproate and benzodiazepines 
5. Exacerbation by GABAergic drugs (GABAA and GABAB agonists, GABA 
transaminase inhibitors) 
6. Blockade by GABAB antagonists 
7. SWDs originating from thalamus or cortex 
8. Hippocampus is silent during seizure activity 
 
Animals of the GAERS strain spontaneously display many of the characteristics of 
human absence seizures. (1) As described before, spontaneous synchronous SWDs 
occur bilaterally accompanied by behavioral immobility and lowering of the head 
(Rudolf, Bihoreau et al. 2004). (2) The epilepsy phenotype is polygenetically 
determined in an autosomal dominant inheritance (Micheletti, Vergnes et al. 1985; 
Manning, Richards et al. 2004) leading to a reproducible and predictable animal 
model. (3) EEG measurements allow quantification of seizure occurrence. (4) SWDs 
in GAERS are suppressed by ethosuximide, valproate and diazepam in a dose-
dependent manner whereas carbamazepine and phenytoin are ineffective or 
aggravate seizures. Phenobarbital is only effective in small doses but loses its effect 
with higher doses (Danober, Deransart et al. 1998). (5) Additionally, SWDs are 
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aggravated by treatment with vigabatrin (GABA transaminase blocker), tiagabine 
(GABA-reuptake inhibitor), muscimol (GABAA agonist) and R-baclofen (GABAB 
agonist, Marescaux, Vergnes et al. 1992). (6) In contrast, GABAB antagonists 
suppress SWDs (Vergnes, Marescaux et al. 1990). (7) SWDs are predominantly 
located in a specific neuronal network involving cortical and thalamic areas whereas 
(8) no SWD was ever recorded from the hippocampus or any limbic structure 
(Polack, Guillemain et al. 2007). Discharges are initiated in deep layer 
somatosensory cortical neurons and spread within the thalamocortical network 
(Seidenbecher, Staak et al. 1998). During fully grown SWDs, burst discharges in the 
cortex significantly lag behind their thalamic counterparts which are responsible for 
the rhythmogenesis (Danober, Deransart et al. 1998). None of these two structures 
can sustain the SWDs alone (Manning, Richards et al. 2003).  
All these investigations confirm that GAERS fulfill the requirements for a genetically 
based experimental model of human absence epilepsy. A great advantage of this 
genetic model is that seizures occur spontaneously and reflect therefore the 
underlying pathophysiology of human absence seizures (Loiseau 1992).  
A major discrepancy between absence seizures in GAERS and humans is the age at 
onset. In humans, as mentioned above, childhood absence epilepsy develops before 
the age of 10 years and tends to disappear in puberty or adulthood (Depaulis and 
Van Luijtelaar 2005). Contrary in GAERS, SWDs start after full electrocortical 
maturation (around the 30th postnatal day) and persist until death (Snead, Depaulis et 
al. 1999). This dichotomy is not surprising, since the maturation of human 
thalamocortical circuitry differs profoundly from those of rats (Seidenbecher, Staak et 
al. 1998). Another incongruity is the higher frequency of SWDs in GAERS as 
compared to human patients and the almost complete lack of polyspikes in SWDs 
(Danober, Deransart et al. 1998). SWD frequency seems to be species-dependent 
(Jobe, Mishra et al. 1991). 
In conclusion, GAERS are helpful for further exploring the pathogenesis of and 
developing novel drugs for human absence epilepsy although this animal model does 
not completely mimic human SWDs (Nawa, Carnahan et al. 1995). 
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1.3  Neurotrophins 
Neurotrophins are a family of secreted proteins that play a crucial role in the control 
of neuronal numbers and dendritic growth consisting of nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT3) and neurotrophin-4/5 
(NT4/5, for review see Bibel and Barde 2000). After synthesis in the endoplasmatic 
reticulum, pro-neurotrophins (30-35kDa) are folded, sorted into the constitutive or 
regulated secretory pathway and transported to the appropriate subcellular 
compartment (Blumenfeld 2005). They are cleaved by metalloproteinases to mature 
proteins (12-13kDa) which often build noncovalently linked homodimers as active 
forms (for review see Bibel and Barde 2000). At least some neurotrophin subunits 
are able to form heterodimers (Huang and Reichardt 2001). Neurotrophins are 
secreted by both neuronal and non-neuronal cells (Morimoto, Fahnestock et al. 2004) 
in limited quantities resulting in a competition between innervating neurons. Only 
neurons with the appropriate synapses will survive (Tapia-Arancibia, Rage et al. 
2004). Both, pro-neurotrophins and mature forms have biological activity (Kalb 2005) 
eliciting diverse but specific responses and regulating the structure and function of 
the nervous system throughout development and adulthood. Neurotrophins are 
involved in the correct morphologic, physiologic and chemical differentiation of 
neurons (Wirth, Patz et al. 2004), in cell fate decisions, axon growth, dendrite 
pruning, synaptic function and plasticity (Huang and Reichardt 2001). They also exert 
completely opposite actions such as proliferation or withdrawal from cell cycle, 
growth or shrinkage, survival or apoptosis (Dechant 2001). Rapid changes in 
synaptic activity seem to be mediated by activation of second messengers whereas 
differentiation occurs slowly through induction of new gene expression (Finkbeiner, 
Tavazoie et al. 1997). 
 
1.3.1  Brain-derived neurotrophic factor (BDNF) 
BDNF protein is expressed throughout the brain with highest concentration in 
hippocampus, followed by hypothalamus, septum, tectum, entorhinal cortex, frontal 
cortex, cerebellum, hindbrain, thalamus and striatum (Nawa, Carnahan et al. 1995; 
Conner, Lauterborn et al. 1997). BDNF distribution in soma, dendrites, fibers and 
nuclei suggests that BDNF enters the nucleus of neurons to directly influence 
transcription (Tapia-Arancibia, Rage et al. 2004). Translational and/or post-
translational regulation of BDNF production or cellular transport of BDNF protein 
might influence relative regional disparities in protein and mRNA levels (Nawa, 
Carnahan et al. 1995). 
BDNF is involved in several physiological and pathological processes. Various kinds 
of brain insults such as stress, ischemia and seizure activity alter BDNF expression 
in the central nervous system. Accordingly, changes in its expression contribute to 
different pathologies such as epilepsy, depression, eating disorders, Alzheimer’s and 
Parkinson’s disease (Tapia-Arancibia, Rage et al. 2004). 
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1.3.2  Neurotrophin receptors 
Two different classes of transmembrane receptor proteins bind neurotrophins: the 
tropomyosin-related tyrosine kinase receptors (Trks) and the neurotrophin receptor 
p75 (p75NTR). These receptors are able to interact allowing the transduction of very 
different signals following ligand binding.  
 
Trks are a family of tyrosine kinase receptors consisting of TrkA which preferentially 
binds NGF, TrkB that prefers BDNF as well as NT4/5 and finally TrkC that binds NT3. 
However, NT3 is also able to interact with TrkA or TrkB and NT4/5 with TrkA (figure 
5A). Trks have a size of about 140kD and express high affinity binding sites for 
neurotrophins (Kd~10-11M). Binding of neurotrophins leads to receptor dimerization 
resulting in phosphorylation of specific tyrosine residues which act as docking sites 
for adapter proteins. Three main signaling cascades may be activated: (i) The 
Ras/Raf/extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase 
(MAPK) pathway induces differentiation and neurite growth presumably via cAMP-
response element binding protein (CREB) phosphorylation. (ii) Phosphoinositide 3-
kinase (PI3K) activates protein kinase B or AKT kinases which in turn phosphorylate 
and therefore inactivate the proapoptotic protein Bcl-2 associated death promoter 
(BAD). (iii) The phospholipase Cγ (PLCγ)/inositol 1,4,5-triphosphate (IP3)/Ca2+ 
pathway leads to neurotrophin release and synaptic plasticity. Activation of these 
pathways induces prevention of programmed cell death and neuronal differentiation. 
Neurons are also able to internalize neurotrophins in a receptor-dependent way and 
transport them retrogradely to the cell body. Trk receptors are expressed in a 
selective pattern leading to the exquisite neuronal specificity of neurotrophins (for 
reviews see Klesse and Parada 1999; Bibel and Barde 2000; Kaplan and Miller 
2000). BDNF binding to TrkB is also able to evoke membrane depolarization through 
rapid activation of Nav1.9 sodium channels. This mechanism does not require second 
messengers resulting in a rapid response without attenuation (Blum, Kafitz et al. 
2002) and contributes to long-lasting potentiation of glutamatergic inputs (Scharfman 
2005). Precursor forms of neurotrophins also bind to their specific Trk receptor and 
exert physiological activities (Fayard, Loeffler et al. 2005). 
 
p75NTR, a member of the tumor necrosis factor receptor superfamily, binds 
neurotrophins with low affinity (Kd~10-9M) and mediates cell death independently 
from Trks. Pro-neurotrophins bind with higher affinity to p75NTR than the mature 
forms. This binding site is formed by a complex of p75NTR and sortilin (figure 5B, Kalb 
2005). Signaling pathways of p75NTR are different with nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) activation preventing cell death or 
caspase activation mediating apoptosis. p75NTR expression is down-regulated during 
postnatal development but rapidly induced after nerve lesion or seizures (for review 
see Bibel and Barde 2000).  
 
Ligands, receptors and their intracellular target proteins are linked by balanced 
biochemical interactions. Neurotrophin receptors form three different types of 
complexes: homodimers of Trk receptors, clusters of p75NTR receptors and a mixed 
complex containing both Trk and p75NTR (figure 5). TrkA, TrkB or TrkC receptor 
complexes may cross-talk to each other through p75NTR which provides a physical 
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link between them (Dechant 2001). The proapoptotic signals of p75NTR are largely 
suppressed by simultaneous activation of Trk receptors. p75NTR appears to refine the 
ligand-specificity of Trk receptors. It can even potentiate the activation of TrkA by 
subsaturating concentrations of NGF. Thus, p75NTR promotes elimination of neurons 
that are not exposed to appropriate levels of neurotrophins (Huang and Reichardt 
2001).  
 
 
 
Figure 5: Interactions of neurotrophins with different receptor complexes. A, 
NGF binds selectively to TrkA homodimers. NT3 has highest affinity to TrkC, but is 
also able to activate TrkA or TrkB homodimers. BDNF and NT4/5 preferentially bind 
to TrkB. All neurotrophins activate with low affinity a p75NTR receptor complex. B, 
Heterodimers with p75NTR increase affinity and selectivity of Trks for neurotrophin 
binding. Pro-forms of neurotrophins bind with high affinity to a heterodimer consisting 
of sortilin and p75NTR.   
 
1.3.3  BDNF in epilepsy 
Previous studies have shown that BDNF signaling is associated with epilepsy. BDNF 
appears to be both regulated by and a regulator of epileptogenesis. 
BDNF mRNA or protein levels are significantly increased after epileptic stimuli as 
shown for limbic seizures induced by electrolytic lesions of the dentate gyrus (DG, 
Xapelli, Bernardino et al. 2008), non-convulsive doses of GABAB receptor 
antagonists (Heese, Otten et al. 2000), kainic acid (Zafra, Lindholm et al. 1992), 
pilocarpine (Kornblum, Sankar et al. 1997), flurothyl kindling (Mhyre and Applegate 
2003) and after febrile seizures (Kim, Rhyu et al. 2001). After seizures, BDNF mRNA 
and protein are accumulated in dendrites of hippocampal neurons (Tongiorgi, 
Armellin et al. 2004). 
Additionally, TrkB and TrkC, but not TrkA mRNA expression are concomitantly and 
transiently increased after focal and generalized seizures induced by hippocampal or 
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amygdala kindling (Bengzon, Kokaia et al. 1993). These changes are accompanied 
by a striking but transient induction of Trk phosphorylation in mossy fiber axons of 
dentate granule cells (Binder, Routbort et al. 1999). Expression of p75NTR is highly 
induced in neurons and microglia within the sclerotic hippocampus of 
pharmacoresistant patients with temporal lobe epilepsy (Ozbas-Gerceker, Gorter et 
al. 2004). 
The impact of BDNF on epileptogenesis has been proven in several genetic modified 
mice models. Transgenic mice overexpressing BDNF are more susceptible to kainic 
acid-induced seizures and show hyperexcitability in hippocampal area CA3 and 
entorhinal cortex (Croll, Suri et al. 1999). In line with these results, transgenic mice 
overexpressing TrkB which leads to increased BDNF signaling experience more 
severe status epilepticus and have acute neuronal loss after kainic acid treatment. In 
contrast, the chronic increase in BDNF signaling does not alter the development of 
spontaneous seizures in transgenic mice. Changes in BDNF levels in the long run 
may be compensated by adjustments to the higher basal levels of TrkB signaling, 
whereas sudden changes such as occurring during status epilepticus cannot be 
antagonized (Lahteinen, Pitkanen et al. 2003). 
Homozygous deletion of BDNF is lethal in knock-out mice, therefore heterozygotes 
showing a reduction of BDNF mRNA in cerebral cortex have been studied. Kindling 
development is markedly retarded in these mice reflecting dampening of the 
progression from focal to generalized seizures. In contrast, persistence of kindling is 
unaffected (Kokaia, Ernfors et al. 1995). Additionally, these mice have lower seizure 
susceptibility for limbic (6Hz), pentylenetetrazol- and kainic acid-induced seizures, 
but higher susceptibility to pilocarpine-induced seizures suggesting that lack of BDNF 
can confer resistance to some, but not all types of seizures (Barton and Shannon 
2005). In line with these results, transgenic mice overexpressing truncated TrkB, a 
dominant negative receptor of BDNF, have less severe seizures with later onset and 
lower mortality after induction of status epilepticus by kainic acid (Lahteinen, 
Pitkanen et al. 2002). 
The results obtained from genetic mice models have been corroborated by 
intracerebral injection studies. In the kindling paradigm, seizure scores are 
significantly higher in animals receiving multiple BDNF microinjections (Xu, Michalski 
et al. 2004). In contrast, chronic intrahippocampal infusion of BDNF delays the 
progression of hippocampal kindling, whereas infusion of BDNF antisense 
oligodeoxynucleotides aggravates seizures (Reibel, Larmet et al. 2000b). These 
discrepancies can be explained by investigating BDNF signaling pathways. Multiple 
bolus microinjections of BDNF do not affect TrkB, whereas continuous infusion of 
BDNF drastically decreases phosphorylation and expression of TrkB receptors thus 
leading to an attenuation of epileptogenic effects of BDNF (Xu, Michalski et al. 2004). 
Furthermore, continuous infusion of high BDNF concentrations may overcome the 
inhibition caused by TrkB receptor down-regulation and increases therefore 
excitability after pilocarpine injection and causes spontaneous seizures (Scharfman, 
Goodman et al. 2002). 
Activation of Trk receptors and downstream-signaling play an important role in 
epileptogenesis. Perforant path kindling is significantly inhibited by blocking 
selectively TrkA, but not p75NTR receptors (Li, Saragovi et al. 2005). Only a modest 
impairment of limbic epileptogenesis is detected in BDNF knock-out mice, whereas 
no behavioral seizures occur in TrkB knock-out mice suggesting that compensatory 
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increases in NT3 expression may contribute to TrkB activation and epileptogenesis in 
BDNF knock-out mice (He, Kotloski et al. 2004). 
In conclusion, these data support the hypothesis that BDNF predisposes the brain to 
epileptic seizures. Scharfman (2005) hypothesizes that increased levels of BDNF 
potentiate glutamatergic transmission leading to increased neuronal activity which in 
turn increases secondarily BDNF and TrkB levels. These events escalate by positive 
feedback and finally reach seizure threshold. Additionally, the seizure-induced 
increase of BDNF synthesis may constitute an intrinsic protective response 
counteracting cell death (Kokaia, Ernfors et al. 1995). 
 
1.3.4  Mechanisms underlying the anticonvulsant effects of 
BDNF 
BDNF induces a rapid and long-lasting enhancement of synaptic transmission at 
mature synapses (Kang and Schuman 1995) by increasing glutamate release via 
PLCγ/Ca2+ pathway (Toth 2005). Additionally, the regulated stimulation-evoked 
release of glutamate is increased in BDNF-treated cultured cortical neurons due to 
elevated expression of exocytosis-associated proteins and synaptic vesicles (Takei, 
Sasaoka et al. 1997).  
In contrast, BDNF inhibits GABAA-receptor mediated inhibitory post-synaptic currents 
in rat hippocampal slices facilitating neural excitation and generation of action 
potentials (Tanaka, Saito et al. 1997; Frerking, Malenka et al. 1998). 
BDNF upregulation also mediates mossy fiber sprouting via activation of TrkB and 
Ca2+ release. Sprouting of mossy fibers generates a proepileptic recurrent circuit and 
is often seen in patients with TLE (Koyama, Yamada et al. 2004). 
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1.4  3’,5’-cyclic adenosine monophosphate (cAMP)-
response element binding protein (CREB) 
Most of the mechanisms underlying neuronal reorganization are mediated via gene 
activation. The transcription factor CREB is ubiquitously expressed and a target for 
numerous signaling cascades that cause phosphorylation on the CREB activator site 
serine 133. This process causes a conformational change of the CREB molecule and 
allows pCREB to bind as dimer to certain DNA sequences called cAMP-response 
elements (CRE) in the promoters of many genes to modulate their transcription 
(Montminy, Gonzalez et al. 1990). CREB regulates the expression of different 
proteins as e.g. GABAB receptors (Steiger, Bandyopadhyay et al. 2004), the proto-
oncogene c-fos, somatostatin, tyrosine hydroxylase, vasoactive intestinal peptide, 
pro-enkephalin and chorionic gonadotropin. Moreover, cellular morphology, 
intermediary metabolism and neuropeptide biosynthesis are affected (Montminy, 
Gonzalez et al. 1990). Thus, CREB plays an important role in neuronal connectivity 
and excitability leading finally to changes in the neuronal network (Chen, Chang et al. 
2006). Within minutes after Ca2+ signals terminate, CREB is dephosphorylated and 
signaling pathways are stopped. CREB acts therefore as an on-off switch for gene 
expression (Chawla and Bading 2001).  
 
1.4.1  Interaction between CREB and BDNF 
CREB plays a major role in the realization of neurotrophin responses. Neurotrophins 
utilize at least two pathways for activating CREB by phosphorylation at serine 133. In 
a rapid signaling mechanism, activation of TrkB stimulates PLCγ resulting in 
production of IP3 which in turn releases intracellular Ca2+ leading to activation of 
calcium/calmodulin-dependent kinases (CaMK). The second slower signaling 
pathway includes activation of the Ras/ERK/ribosomal s6 kinase (RSK) cascade 
(figure 6). These different mechanisms enable BDNF to regulate specific neuronal 
functions and to broaden the number of genes responsive to BDNF (Finkbeiner, 
Tavazoie et al. 1997). BDNF-induced signaling pathways outlast the presence of 
BDNF due to the slow mechanism via Ras/ERK/RSK (Chawla and Bading 2001). 
Additionally, this pathway appears to be involved in BDNF-induced long-term 
memory formation (Alonso, Vianna et al. 2002).  
BDNF does not only regulate transcription of genes via phosphorylation of CREB, it 
is also a CREB target gene by itself. Conti et al. (2002) showed in mice that CREB 
functions also as an upstream activator of BDNF expression. 
 
1.4.2  Interaction between CREB and neuropeptide Y (NPY) 
CREB is also involved in the signal transduction of NPY effects (Chance, Sheriff et 
al. 2000). Sheriff et al. (1998; 2002) showed that NPY mediates CREB 
phosphorylation and CRE binding via activation of Y1 and Y2 receptors leading to an 
increase in intracellular [Ca2+] and activation of protein kinase A (PKA) or CaMK 
(figure 6). Additionally, NPY expression itself is also regulated by CREB (Pandey 
2003; Hsieh, Yang et al. 2007). 
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Figure 6: Interactions between BDNF, CREB and NPY. BDNF binding to TrkB 
activates two signaling mechanisms: (i) Stimulation of phospholipase Cγ (PLCγ) 
produces inositol 1,4,5-triphosphate (IP3) which in turn releases intracellular Ca2+. 
Calcium/calmodulin-dependent kinases (CaMK) are activated by increased 
intracellular [Ca2+]. (ii) The second signaling pathway involves phosphorylation of the 
proto-oncogene Ras, the extracellular signal-regulated kinases (ERK) and the 
ribosomal s6 kinase (RSK). Both pathways activate CREB and influence gene 
expression. Activated NPY-receptors (NPYR) lead to a direct phosphorylation of 
CREB via protein kinase A (PKA) or indirectly via elevation of intracellular [Ca2+]. 
BDNF and NPY expression are both regulated themselves by the transcription factor 
CREB.  
 
1.4.3  CREB in epilepsy 
The function of CREB in epileptogenesis is still not clarified. The number of pCREB-
positive nuclei significantly decreases 24 hours and CREB mRNA expression 30 
days after pentylenetetrazol-induced kindling in chronic epilepsy rats (Lou, Wang et 
al. 2007; Wang, Lou et al. 2008). Increases in seizure susceptibility to 
pentylenetetrazol of Sprague-Dawley rats by perinatal hypoxia are accompanied by 
decreases in CREB phosphorylation in midbrain, temporal cortex and hippocampus 
(Chen, Chang et al. 2006). Phosphorylation of CREB in hippocampal CA1 is also 
diminished 60 days after lithium-pilocarpine induced status epilepticus in Sprague-
Dawley rats (Huang, Lai et al. 2003).  
In contrast, increased CREB binding activity was demonstrated 2 hours after 
amygdala kindling in hippocampus (Kashihara, Sato et al. 2000). 
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1.5  Neuropeptides 
Neuropeptides are a class of signaling molecules that often act as cofactors of 
classical transmitters including glutamate or GABA and are therefore important 
modulators of neuronal excitability (Wilson, Chung et al. 2005). They are synthesized 
as pro-forms in perikarya and wrapped into vesicles. Afterwards, they are transported 
to nerve endings, cleared by proteases and released by exocytosis. Neurons are not 
competent for neuropeptide reuptake, thus they have to continuously rebuild and 
transport them de novo (Sperk 2006). 
 
1.5.1  Neuropeptide Y 
NPY consists of 36 amino acids with tyrosine as its N-terminal, tyrosine amide as its 
C-terminal and a total of five tyrosine residues per molecule (figure 7). It is a member 
of the pancreatic polypeptide family having structural similarities with the peptide YY 
and the pancreatic polypeptide (Tatemoto, Carlquist et al. 1982). It is generated as 
pre-pro-NPY, then the signal peptide is removed in the endoplasmatic reticulum and 
the pro-form is cleaved by prohormone convertases. Functions of NPY include 
regulation of appetite, anxiety, sedation, epilepsy, circadian rhythms, memory 
processing, pain, drug addiction, blood pressure, rhinitis and endothelial cell 
dysfunctions (for review see Silva, Cavadas et al. 2002) 
 
 
 
Figure 7: Structure of human neuropeptide Y. NPY is a tyrosine rich protein 
consisting of 36 amino acids (from the protein data base according to the work of 
Monks, Karagianis et al. 1996). 
 
NPY is widely distributed throughout the central and peripheral nervous system and 
represents the most abundant neuropeptide in brain although the levels are low. It is 
co-localized in GABA-containing interneurons. Structures with highest levels of NPY 
mRNA are the hypothalamus, cerebral cortex and hilar region of the hippocampus. In 
addition, the majority of the perikarya in nRT expresses NPY mRNA (Nakagawa, 
Shiosaka et al. 1985), but not in the ventrobasal nucleus of the thalamus (Redrobe, 
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Dumont et al. 1999), whereas NPY-positive fibers are detected in several thalamic 
nuclei in rats (Walter, Mai et al. 1990). In human thalamus, NPY immunoreactivity is 
concentrated in the area of the midline nuclei, whereas immunoreactive fibers are 
found in various nuclei (Patrylo, van den Pol et al. 1999).  
NPY is located within dense core vesicles (Pickel, Chan et al. 1995) that are believed 
to be released during high-frequency firing (Hokfelt 1991). Thus NPY may be 
released during epilepsy thereby limiting seizure severity (Brill, Lee et al. 2006). 
 
1.5.2  NPY receptor subtypes 
NPY signals through a family of G-protein-coupled receptors: Y1, Y2, Y3, Y4, Y5 and 
Y6; the latter is not functional in humans (Silva, Cavadas et al. 2002).  
Colocalization of the receptor subtypes to the same region of a chromosome 
suggests that these subtypes have a common origin despite their structural 
differences (Ammar, Eadie et al. 1996). Distribution and expression of NPY receptor 
subtypes vary between species (Redrobe, Dumont et al. 1999).  
 
Y1 receptor subtype is mainly expressed in blood vessels and the central nervous 
system, preferentially in frontoparietal cortex and thalamus (Dumont, Fournier et al. 
1993; Silva, Cavadas et al. 2002). In hippocampus, moderate levels are found in the 
molecular layer of DG. High levels of Y1 receptor mRNA are restricted to the 
pyramidal cell layers of CA1, CA2 and CA3, whereas low levels were found in the 
granule cell layer of DG (Redrobe, Dumont et al. 1999). 
The N-terminal part of NPY determines its affinity on the Y1 receptor. 
Vasoconstriction is the main effect mediated by this receptor subtype (Silva, Cavadas 
et al. 2002). Additionally, it promotes proliferation of neuronal precursor cells (Hansel, 
Eipper et al. 2001). 
Postsynaptic Y1 receptors are proposed to reduce the excitability of neurons by 
activating G-protein-activated inwardly rectifying potassium (GIRK) channels in 
thalamic nuclei resulting in long lasting hyperpolarization (Sun, Akk et al. 2001; Brill, 
Kwakye et al. 2007). Furthermore, Y1 operates as autoreceptor regulating NPY 
release from interneurons (Baraban 2004). 
 
Y2 receptors are expressed in the central and peripheral nervous system, intestine 
and certain blood vessels (Silva, Cavadas et al. 2002). In hippocampus, high 
expression levels of Y2 receptor mRNA are found throughout the pyramidal cell layer 
of each CA region, whereas expression is moderate in the granule cell layer and only 
very low in the molecular layer of DG (Redrobe, Dumont et al. 1999). 
Activation of presynaptic Y2 receptors reduces intracellular [Ca2+] (Qian, Colmers et 
al. 1997) and inhibits the K+-stimulated and Ca2+-dependent glutamate release in rat 
hippocampal slices (Greber, Schwarzer et al. 1994). In contrast, Y2 receptor 
mediated inhibition of Ca2+-influx downregulates GABA release in thalamic nuclei 
(Sun, Akk et al. 2001). 
 
Y3 receptor subtype is localized in the human adrenal medulla where it mediates 
NPY-induced secretion of catecholamines (Silva, Cavadas et al. 2002).  
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Y4 receptors are widely distributed throughout the whole body. Its expression in rat 
hippocampus is very limited and restricted to few specific neurons. Highest mRNA 
expression is detected in the pyramidal cell layer of CA3. Nevertheless, Y4 receptor 
mRNA is found in low levels in pyramidal neurons of all three CA regions and in 
granule cells of DG (Redrobe, Dumont et al. 1999). 
Y4 receptor binds the pancreatic polypeptide with a higher affinity than NPY and 
seems therefore to be involved in the effects described for pancreatic polypeptide as 
inhibition of exocrine pancreatic secretion, induction of gall bladder relaxation and 
stimulation of luteinizing hormone secretion (Silva, Cavadas et al. 2002). 
 
Y5 receptors are preferentially expressed in many peripheral organs and in 
hypothalamus where they stimulate appetite (Silva, Cavadas et al. 2002). 
Y5 receptor mRNA is only expressed in regions where Y1 receptor mRNA is 
detected (Parker and Herzog 1999). In rat hippocampus, its mRNA is found in high 
levels throughout the pyramidal cell layers of all CA regions with peak levels in CA3. 
Y5 receptors are also expressed in significant amounts in the molecular layer of DG 
although levels are lower than the one of the Y1 receptor subtype (Rodi, Mazzuferi et 
al. 2003).  
 
1.5.3  NPY in epilepsy 
NPY expression undergoes drastic changes following epileptic seizures. Its protein 
levels decline immediately after seizure onset reflecting an enhanced release by 
seizure activity (Xapelli, Bernardino et al. 2008). This decrease occurs as 
neuropeptides do not undergo reuptake by neurons after their release. Thereafter, 
NPY is newly synthesized and NPY levels markedly increase. Changes in NPY 
expression following seizures occur only in brain regions that are crucial for the 
initiation and propagation of epileptic discharges (Vezzani, Sperk et al. 1999b) and 
represent an endogenous adaptive mechanism to counteract hyperexcitability 
(Vezzani and Sperk 2004). 
Delayed and long-lasting increases in NPY expression are observed after severe 
kainic acid induced limbic seizures (Marksteiner, Sperk et al. 1989; Wilson, Chung et 
al. 2005; Brill, Lee et al. 2006), pentylenetetrazol-kindling (Marksteiner, Lassmann et 
al. 1990) and hyperthermic seizures (Kang and Macdonald 2004). Additionally, febrile 
seizures induce a release of endogenous NPY which in turn reduces the network 
excitability and increases threshold for further febrile seizures (Dube 2007). Elevated 
NPY immunoreactivity is also found in genetic animal models as Ihara’s genetically 
epileptic rats which display spontaneous convulsions (Takahashi, Sadamatsu et al. 
1997) and in Noda epileptic rats suffering from spontaneous generalized tonic-clonic 
seizures (Jinde, Masui et al. 2002). 
Not only significant increases in NPY mRNA occur during kindling epileptogenesis, 
but also drastic cell- and region-specific changes in receptor expression. Rapid and 
transient decreases in Y1 mRNA are observed, whereas Y2 mRNA is elevated. Y5 
mRNA expression is only transiently increased (Kopp, Nanobashvili et al. 1999). 
Similar changes occur in Noda epileptic rats (Jinde, Masui et al. 2002). In kainic acid-
induced seizures, Y5 receptor protein is reduced accompanied by pyramidal and hilar 
cell loss (Vezzani, Moneta et al. 2000). During epileptogenesis, down-regulation of 
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Y1 receptors may favor the inhibitory effects of NPY mediated by Y2 receptors which 
are up-regulated. 
NPY has also received considerable attention as an endogenous modulator of 
epileptic activity as corroborated by several genetic animal models. Rats 
overexpressing NPY show a significant reduction in the number and duration of 
seizures induced by kainic acid and an increase in electrical stimuli required to 
induce stage 5 seizures during kindling (Vezzani, Michalkiewicz et al. 2002). In 
accordance, adeno-associated virus vector mediated overexpression of NPY in rats 
reduces seizures induced by intrahippocampal kainic acid, delays seizure onset and 
impairs kindling epileptogenesis (Richichi, Lin et al. 2004). Additionally, selective 
down-regulation of Y1 receptors by infusion of antisense oligonucleotides 
significantly slows down hippocampal kindling development. In contrast, Y1 knock-
out mice have a similar susceptibility to hippocampal kindling as control rats 
suggesting that compensatory mechanisms exist (Benmaamar, Pham-Le et al. 
2003). Intrahippocampal administration of an Y1 receptor antagonist significantly 
reduces susceptibility to kainic acid, whereas an Y1 receptor agonist evokes wet dog 
shakes (Gariboldi, Conti et al. 1998). In line with these results, kainic-acid induced 
seizures progress uncontrollably finally leading to death in almost all NPY-deficient 
mice. Death can be prevented by intracerebroventricular (icv) infusion of NPY 
(Baraban, Hollopeter et al. 1997). Additionally, NPY-deficient mice are more 
susceptible to pilocarpine-induced seizures and kindling development (Shannon and 
Yang 2004). 
In vitro and in vivo studies support the role of NPY as an endogenous anticonvulsant. 
Injection of NPY prior to kainic-acid significantly reduces total time spent in seizure 
and severity of seizures whereas latency to the first long lasting and grade 4/5 
seizure is prolonged (Madsen, Woldbye et al. 1999). Chronic intrahippocampal 
infusion of NPY delays the progression of hippocampal kindling, whereas application 
of anti-NPY immunglobulins accelerates the development of generalized convulsive 
seizures (Reibel, Benmaamar et al. 2003). Additionally, NPY inhibits behavioral 
effects evoked by injection of the GABAA-antagonist picrotoxin (Woldbye, Madsen et 
al. 1996). NPY and an Y2 receptor agonist reduce the frequency of spontaneous 
epileptiform discharges induced by picrotoxin in rat hippocampal slices suggesting 
that the antiepileptic effect is mediated by activation of Y2 receptors (Smialowska, 
Bijak et al. 1996). Icv applied NPY reduces the duration of afterdischarges following 
electrical stimulation in rat. Additionally, afterdischarge threshold is increased and 
accompanying wet dog shakes are blocked (Marksteiner and Sperk 1988). In 
epileptic humans, NPY is able to attenuate excitatory responses provoked by 
perforant path stimulation in DG and may be effective in reducing glutamate-
mediated hyperactivity (Smialowska, Bijak et al. 1996). Recent data also implicate 
the involvement of NPY in the occurrence of absence seizures (Stroud, O'Brien et al. 
2005; Morris, Gannan et al. 2007). 
The neuroprotective effects of NPY highlight the possibility of developing novel 
therapeutic strategies for the treatment and management of intractable seizures. 
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1.5.4  Mechanisms underlying the antiepileptic effects of 
NPY 
Exogenously applied NPY on neocortical slices of rats leads to a delayed and long-
lasting potentiation of inhibitory post-synaptic currents and a depression of excitatory 
post-synaptic currents in pyramidal neurons by enhancing the GABA release (Frank, 
Ventimiglia et al. 1996) and suppressing depolarization-induced glutamate release 
(Richichi, Lin et al. 2004). NPY was shown to induce at least three different 
intracellular signaling events: (i) inhibition of adenylyl cyclase, (ii) variation of 
intracellular [Ca2+] via IP3 or direct activation or blocking of Ca2+ channels and (iii) 
activation or inhibition of K+ channels (Silva, Cavadas et al. 2002). 
The involvement of different NPY receptor subtypes in the antiepileptic effect is 
discussed controversially. Sun et al. (2003) propose that slow IPSPs in GABAergic 
nRT neurons are mediated by NPY binding to Y1 receptors leading to activation of 
GIRK channels causing a negative feedback for activity in the thalamic network and 
therefore suppression of epileptiform activity. In contrast, NPY released in the 
hippocampus following seizures exerts a proconvulsive action via Y1 receptors which 
are located on granule cells in the DG (Vezzani, Sperk et al. 1999b). 
Y2 receptors are involved in the antiepileptic effect via reduction of glutamate outflow 
in synaptosomes of kindled rats (Colmers, Klapstein et al. 1991). NPY reversibly 
inhibits excitatory synaptic transmission from stratum radiatum to CA1 pyramidal cells 
via Y2 receptors (McQuiston, Petrozzino et al. 1996). During prolonged seizures, 
NPY is also spontaneously released from mossy fibers and subsequently by 
activating presynaptic Y2 receptors, glutamate release and granule cell epileptiform 
activity are reduced (Nadler, Tu et al. 2007).  
Finally, other studies show that the Y5 receptor subtype also mediates anticonvulsant 
properties of NPY. In rat hippocampal slices, Y5 receptors play a major role in 
mediating NPY-exerted suppression of spontaneous bursting (Nanobashvili, Woldbye 
et al. 2004). Suppressive effects of NPY on kainic acid-induced seizures in rats are 
also mediated via Y5-like receptors (Woldbye, Larsen et al. 1997). Concomitantly, 
NPY has no effect on epileptiform activity recorded in hippocampal slices from Y5 
receptor knock-out mice (Baraban 2002). 
An extensive study that used in vitro and in vivo studies in rats and wild-type as well 
as knock-out mice confirms the involvement of Y2 receptors in the anticonvulsant 
effect of NPY, whereas involvement of Y5 receptors is not supported (El Bahh, 
Balosso et al. 2005). 
In conclusion, Woldbye and Kokaia (2004) reviewed that Y2 and/or Y5 receptor 
agonists and Y1 receptor antagonists appear to inhibit seizures depending on the 
seizure model studied. 
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1.6  Interaction between BDNF and NPY 
Icv administration of BDNF on newborn rats significantly increases NPY 
immunoreactivity and mRNA expression suggesting that BDNF induces NPY 
synthesis (Nawa, Pelleymounter et al. 1994). In line with this result, NPY-expression 
is long-lasting increased after chronic intrahippocampal infusion of BDNF in rats 
(Reibel, Larmet et al. 2000a; Scharfman, Goodman et al. 2002). Wirth et al. (2005) 
propose that BDNF is not able to induce NPY in the absence of activity. For induction 
of NPY, a continuous activation of TrkB by BDNF is required. The longer the BDNF 
exposure lasts, the longer the duration of TrkB phosphorylation and induction of the 
signaling pathway ERK that is involved in the induction of NPY (Barnea and Roberts 
2001; Barnea, Roberts et al. 2004). Overexpression of NPY is long-lasting 
suggesting that BDNF can trigger long-term genomic effects and therefore contribute 
to neuroplasticity (Reibel, Vivien-Roels et al. 2000). BDNF and NPY play opposite 
roles in epilepsy. BDNF itself enhances hippocampal excitability, but it also induces 
NPY-expression which in turn blocks seizure propagation (Koyama and Ikegaya 
2005). BDNF released by microglia and neurons can also affect neuroprotection 
against excitotoxicity which is mediated by NPY via Y1 and Y2 receptors (Xapelli, 
Bernardino et al. 2008). BDNF overexpression after AMPA (glutamate receptor 
agonist) exposure might be a response to excitotoxicity and reduces cell damage by 
inducing NPY production. Y2 receptors are thought to play an important role in this 
cross-talk between BDNF and NPY (Morris 1989). 
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2  Aim of this thesis 
 
Epilepsy is currently among the most prevalent neurological disorders worldwide. 
The current treatment focuses exclusively on the prophylaxis or suppression of 
seizures and thus provides merely a symptomatic treatment without clear influence 
on the cause of the disease. There is an urgent need for new drugs that act at 
different molecular targets designed to block the process of epileptogenesis. 
 
Goal of this thesis was to define the potential role of the neurotrophin/neuropeptide-
system (including receptors and signaling pathways) in absence seizures. The 
following criteria are addressed in detail: 
 
• To reveal expression differences in rats suffering from absence seizures, 
biochemical investigations are performed in various brain regions (e.g. cortex, 
thalamus and hippocampus) of adult GAERS as compared to NEC. 
 
• To detect region- and neuronal subpopulation-specific expression patterns of 
neurotrophins and neuropeptides, brain tissue is investigated by 
immunohistochemical analyses. 
 
• To expose differences that are linked to the occurrence of seizures, 
developmental studies are performed in juvenile, 3-4 weeks old GAERS which do 
not yet display SWDs. Early alterations in expression might have important 
consequences on brain development and therefore favor epileptogenesis. 
 
• To verify the impact of expression differences on epileptogenesis, functional 
studies are performed. A dual approach is utilized to define the substances 
involved in possible anti-absence effects. In one series of experiments, effects on 
the initiation of SISWDs in juvenile GAERS are quantified following icv 
microinjection of drugs interfering with the neurotrophin/neuropeptide-system. In a 
further series of experiments, SWDs in adult GAERS are blocked by treatments 
inhibiting the neurotrophin/neuropeptide-system. Functional effects are monitored 
by recording SWDs using EEG measurements. 
 
Results obtained should reveal new insights into the role of neurotrophins and 
neuropeptides in the causes of absence epilepsy. Both of them might represent 
accessible systems in specific brain regions to intervene in the excitability of neurons. 
Thus, novel therapeutic approaches aimed not only at the prevention or treatment of 
absence epilepsy, but also other neurological diseases with disturbed excitability in 
humans might emerge. 
 
The results of my studies are summarized in the two manuscripts “Involvement of the 
brain-derived neurotrophic factor – tyrosine kinase receptor B – neuropeptide Y 
cascade in suppressing absence seizures in a genetic rat epilepsy model.” (red) and 
“On the protective role of neuropeptide Y against spike-and-wave discharges in a 
genetic rat model of absence epilepsy” (green) which are submitted for publication. 
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3  Results 
 
3.1  Part I – Involvement of BDNF-TrkB-NPY in 
absence seizures 
 
 
 
Involvement of the brain-derived neurotrophic factor – 
tyrosine kinase receptor B – neuropeptide Y cascade in 
suppressing absence seizures in a genetic rat epilepsy 
model. 
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Abstract 
 
Genetic Absence Epilepsy Rats from Strasbourg (GAERS) serve as a valid model for 
human generalized non-convulsive seizures according to their 
electroencephalographic, behavioural and pharmacological characteristics. Thus, 
exploring the pathogenesis of spike-and-wave discharges (SWDs) in GAERS may 
lead to a better understanding of the mechanisms underlying human absence 
epilepsy. 
Here, we demonstrate that cortical and hippocampal brain-derived neurotrophic 
factor (BDNF) expression is elevated in adult GAERS as compared to age-matched 
non-epileptic controls (NEC). This is also the case in juvenile GAERS although they 
do not yet display SWDs. Tyrosine kinase receptor B (TrkB) mRNA expression is 
markedly decreased in adult GAERS and concomitantly, protein levels of 
phosphorylated cAMP response element binding protein (pCREB) are strongly 
reduced. Moreover, we found higher mRNA levels of neuropeptide Y (NPY) in cortex 
and hippocampus of both, adult and juvenile GAERS as compared to age-matched 
NEC although it has been demonstrated that NPY suppresses SWDs. In both brain 
areas, density of NPY expressing neurons is more pronounced in juvenile than in 
adult rats, suggesting that occurrence of absence seizures correlates with a 
significant age-dependent decrease of NPY expression. The majority of NPY-positive 
neurons also contain BDNF indicating a close correlation of expression. 
Intracerebroventricular injection of BDNF significantly reduces the occurrence of 
SWDs. 
Taken together, it can be concluded that BDNF signalling is significantly altered in 
adult GAERS and plays an important role in the control of SWDs. 
 
 
Introduction 
 
Among the different types of epilepsy, the pathophysiology of human nonconvulsive 
absence seizures is poorly understood. This type of epilepsy is prevalent during 
childhood and potentially detrimental to the child’s education, social integration and 
health. Studies of the pathophysiological mechanisms of human absence epilepsy 
cannot be conducted in human for ethical reasons (Vergnes et al., 1982). Therefore, 
animal models are mandatory to understand this type of epilepsy and the 
mechanisms underlying the generation and control of spike-and-wave discharges 
(SWDs). The strain Genetic Absence Epilepsy Rats from Strasbourg (GAERS) 
appears to be a genetic model with clinical and pharmacological characteristics 
similar to those occurring in humans (Depaulis & Van Luijtelaar, 2005). In addition it 
is not pharmacologically induced and no neuronal loss has been described (Sabers 
et al., 1996). The hallmark of absence seizures in GAERS is the appearance of 
bilaterally generalized SWDs in the electroencephalogram (EEG). 
The goal of this study was to define the potential role of neurotrophins in generalized 
absence seizures with special regard to expression differences between GAERS and 
control animals as well as changes during maturation. 
The role of brain-derived neurotrophic factor (BDNF) in epileptogenesis is 
controversial. Whereas Reibel et al. (2000b) observed that BDNF could inhibit the 
development of kindling-induced seizures, Scharfman et al. (2002) noted 
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spontaneous limbic seizures after intrahippocampal infusion of BDNF. The latter 
results were corroborated by conditional deletion experiments in the kindling model 
showing that tyrosine kinase receptor B (TrkB) deficiency in hippocampus blocks 
kindling (He et al., 2004). TrkB is activated during epileptogenesis and it may be 
indispensable for the aggravating effect of BDNF (Binder et al., 1999; He et al., 
2002). Controversial data were potentially reconciled by a study of Xu et al. (2004) 
showing that continuous infusion of BDNF downregulates TrkB receptors leading to 
an inhibitory effect on epileptogenesis, whereas bolus injection of BDNF does not 
alter TrkB expression and exerts epileptogenic effects.  
BDNF has also been reported to regulate the expression of the transcription factor 
phosphorylated cAMP response element binding protein (pCREB, Wahlin et al., 
2000) and the potent endogenous antiepileptic transmitter neuropeptide Y (NPY, 
Nawa et al., 1994; Reibel et al., 2000a; Reibel et al., 2003). 
Juvenile GAERS younger than 30 days fail to show SWDs (Vergnes et al., 1986). 
With increasing age the number of animals with SWDs gradually increases and 
reaches 100% at the age of 3 months. Comparing juvenile and adult GAERS and 
age-matched non-epileptic controls (NEC) allows to test whether alterations in the 
cerebral BDNF signalling cascade during brain development contribute to the 
occurrence of SWDs in GAERS by influencing NPY expression (Fig. 1). We 
hypothesize that either, BDNF binding on TrkB receptor results in phosphorylation of 
the receptor inducing the recruitment of a series of signalling proteins and finally 
leading to CREB phosphorylation, or BDNF directly phosphorylates CREB, known to 
act as transcription factor for NPY, or BDNF directly induces NPY expression. 
 
 
 
 
Figure 1. A summary of the signal cascade by which interaction between BDNF 
and NPY counteracts epileptogenesis. BDNF binding to TrkB stimulates receptor 
phosphorylation, resulting in the recruitment of a series of signalling proteins to 
docking sites on the receptor, finally leading to CREB phosphorylation. This 
transcription factor in turn regulates the expression of NPY and BDNF. NPY via 
stimulation of NPY-receptors (probably Y2 receptors) is also competent to activate 
CREB by phosphorylation. Additionally, BDNF might phosphorylate CREB without 
binding to TrkB and/or directly induce NPY expression. 
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Materials and methods 
 
General chemicals used were purchased from Sigma-Aldrich Chemie GmbH (Buchs, 
Switzerland) unless otherwise stated.  
 
Animals 
We performed our studies in juvenile rats at the age of 28-30 days and in adult rats 
older than 3 months. To avoid influence of cyclic changes in female sex hormones on 
BDNF and NPY expression (Scharfman & MacLusky, 2006), only male adult animals 
were used in these experiments. NEC and GAERS are from the original colony from 
Strasbourg and were kindly provided by Prof. C. Marescaux (University of 
Strasbourg, France). They were maintained on an ad libitum feeding schedule, 
housed on a 12h on/12h off light cycle and kept for at least one week on site before 
being used in experiments. All animal tests performed were in accordance with the 
guidelines of the Swiss Federal Veterinary Office. 
 
Dissection of brain regions for biochemical analysis 
The respiratory centre of animals was paralyzed through saturation with CO2 
(Carbagas, Basel, Switzerland). The brain was removed from the skull, dissected and 
brain regions (thalamus, hippocampus, and dorsolateral cortex, comprising mainly 
the sensorimotor cortex) were separated under a dissecting microscope (SZ-PT, 
Olympus, Tokyo, Japan), immediately frozen in liquid nitrogen and stored at -80°C 
until further use. 
 
BDNF, proBDNF, p75NTR and pCREB protein determination by Western blot analysis 
Individual samples were homogenized by sonication in 500µl, 300µl or 200µl RIPA-
buffer (NaCl 150mM, Nonidet P-40 1%, Deoxycholate 0.5%, SDS 0.1%, Tris-HCl 
50mM (pH 8.72), complete EDTA-free protease inhibitor cocktail tablet (Roche 
Diagnostics, Indianapolis, IN, USA), Na4P2O7 20mM, Na3VO4 2mM, NaF 1mM 
(Merck, Darmstadt, Germany)). Afterwards, samples were purified by centrifugation 
for 1min at 16’000xg and for 20min at 50’000xg. Supernatants were further analyzed. 
Protein concentrations were determined using a Coomassie dye-based assay 
(BioRad, München, Germany). 25µg or 50µg of total protein content of homogenates 
were resolved on Bis-Tris gels (Invitrogen, Carlsbad, CA, USA) by electrophoresis at 
90V for 2h. Proteins were then transferred to Hybond® ECL® Nitrocellulose 
membranes (Amersham Pharmacia Biotech, Uppsala, Sweden) for 1h at 30V. For 
immunostaining, membranes were blocked at room temperature in 5% skim milk 
powder in phosphate buffered saline with 0.1% Tween-20 (Acros Organics, New 
Jersey, NJ, USA) for 30min. Incubation with primary antibodies was performed 
overnight at 4°C in 5% skim milk powder solution with the following dilutions: anti-
BDNF 1:2’000 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-proBDNF 
1:2’000 (Alomone Labs, Jerusalem, Israel), anti-p75NTR 1:10’000 (kindly provided by 
Prof. Y.A. Barde, University of Basel, Switzerland), anti-pCREB 1:1’000 and anti-
CREB 1:4’000 (both from Cell Signaling Technology, Beverly, MA, USA). Anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 1:10’000 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was used as housekeeping-protein for 
normalization of protein loading. After three 5min washes, blots were incubated for 
1h at room temperature with the corresponding IgG-HRP-conjugated secondary 
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antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in 5% skim milk 
powder solution. Signal intensities were determined using a chemiluminescence 
system (Roche Diagnostics, Indianapolis, IN, USA) and light emission was absorbed 
using Kodak Biomax XAR films. Images were captured in a MultiImage® Light 
Cabinet and quantified with FluorChem 8000 software (both from Alpha Innotech 
Corporation, Randburg, SA, USA). After subtraction of local background, pixel values 
of specific proteins were normalized to GAPDH values for each sample. 
 
BDNF, TrkB and NPY mRNA determination by quantitative real-time polymerase 
chain reaction (qRT-PCR) 
Total RNA was prepared from rat dorsolateral cortex, hippocampus and thalamus 
using Trizol® Reagent (Invitrogen, Carlsbad, CA, USA) and purified by DNase 
treatment (Promega, Madison, WI, USA) according to the manufacturer’s 
instructions. RNA quality was measured by means of agarose gel electrophoresis. 
First-strand cDNA synthesis was performed using a SuperScript First-Strand 
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instruction with 2μg of total RNA, random hexamers, dNTPs and 
Superscript™ II reverse transcriptase. Reaction mixtures were subjected to PCR 
amplification using primers specific for BDNF, TrkB, NPY and β-actin (QuantiTect®  
Primer Assay (Qiagen, Hilden, Germany)) and Power SYBR® Green PCR Master Mix 
(Applied Biosystems, Foster City, CA, USA) as fluorescent dye. PCR amplifications 
were performed in wells of the ABI Prism 7000 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA) using the following conditions: 2min at 50°C, 
10min at 95°C, followed by 40 cycles consisting of 15s at 95°C and 1min at 60°C. 
Melting curve analyses of PCR products were performed after each experiment to 
detect non-specific amplifications. Negative controls were transcribed both by 
omitting reverse transcriptase or RNA. 
Quantification of RT-PCR results was performed using the comparative Ct method. 
Fluorescence signal intensities were plotted against the number of PCR cycles on a 
semi-logarithmic scale using the ABI Prism 7000 SDS software. A threshold cycle 
(Ct) was designated as the amplification cycle at which the first significant increase in 
fluorescence occurred. The Ct value of each sample was compared with that of β-
actin as internal standard: ΔCt = Ct(target gene) – Ct(β-actin). In a second step, 
samples of GAERS were compared to those of age-matched NEC: ΔΔCt = 
ΔCt(GAERS) – ΔCt(NEC). The change of expression of the target gene in GAERS 
was calculated by the term 2-ΔΔCt. 
 
BDNF, pCREB and NPY immunohistochemistry 
Rats were deeply anesthetized with 0.5ml (juveniles) or 0.6ml (adults) Vetanarcol® 
(Veterinaria AG, Zürich, Switzerland; diluted 1:4 in NaCl 0.9%) and subsequently 
perfused through the ascending aorta with physiological saline followed by a 
phosphate buffered solution containing 0.2% glutaraldehyde and 4% 
paraformaldehyde for 10min and 4% paraformaldehyde in phosphate buffer for 
another 20min. 40µm thick sagittal sections were cut with a vibratome (Microtome 
HM 650V, Microme GmbH, Walldorf, Germany) through the whole brain. Free-
floating sections were treated with 1% sodium borohydride in 0.05M tris buffered 
saline for 10min and 0.4% Triton X-100 in phosphate buffered saline for 90min at 
room temperature (both Merck, Darmstadt, Germany). Immunostaining was 
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performed using primary antibodies against BDNF (1:250, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), the phosphorylated form of CREB (1:100, Cell Signaling 
Technology, Beverly, MA, USA) and NPY (1:2’000, ImmunoStar Inc., Hudson, WI, 
USA) with the avidin-biotin-immunoperoxidase method. Primary antibodies were 
incubated in blocking solutions containing 5% normal goat serum (Vector 
Laboratories Inc., Burlingame, CA, USA) for 72h at room temperature. Incubation 
with goat biotinylated anti-rabbit IgG (H&L, 1:100; Antibodies Incorporated, Davis, 
CA, USA) took place for 2h and with ABC reagent (ABComplex/HRP, Dako 
Cytomation, Glostrup, Denmark; solutions A and B diluted 1:100 in phosphate 
buffered saline) for 90min at room temperature. Tissue-bound peroxidase was then 
developed using 0.03% H2O2 and 0.05% diaminobenzidine (DAB, Acros Organics, 
New Jersey, NJ, USA) as chromogen resulting in a brown (DAB in tris buffered 
saline, pH 7.4) or purple (DAB nickel in 0.1% NiSO4 solution (Merck, Darmstadt, 
Germany), pH 8.6) staining, respectively. Sections were mounted on gelatinized 
slides, dried overnight at 37°C, completely dehydrated in 50% - 70% - 90% - 94% - 
100% ethanol (Synopharm, Barsbüttel, Germany) solutions and cleared in xylol 
(Merck, Darmstadt, Germany). Finally, they were coverslipped with Eukitt® quick-
hardening mounting media.  
As a general rule all sections were processed with identical concentrations of primary 
and secondary antibody solutions, DAB and hydrogen peroxide. Chromogen reaction 
was initially standardized under a microscope to define the length of incubation 
resulting in optimal cell staining with minimal background.  
Double stainings were performed consecutively since the primary antibodies were 
derived from the same species. We used first DAB nickel as chromogen and after 
blocking remaining peroxidase activity with 10% methanol and 0.3% H2O2 in 0.05M 
tris buffered saline for 10min, the whole procedure was repeated using another 
primary antibody and DAB without enhancement as chromogen. 
 
Morphometry  
NPY positive neurons were counted in three sections per animal, using similar 
laterality for all rats. The interface between two sections was 560μm. Brain sections 
were observed at 4fold magnification using a Nikon Eclipse E800 microscope (Nikon 
AG, Egg, Switzerland) interfaced with a ProgRes C14plus camera and pictures taken 
using the image capture software ProgRes Capture Pro 2.5 (Jenoptik, Jena, 
Germany). The three hippocampal subfields dentate gyrus (DG), hippocampal cornu 
ammonis regions 1 and 3 (CA1 and CA3, respectively) as well as the part of the 
frontoparietal cortex directly overlying the hippocampus were manually encircled and 
the areas calculated. The absolute number of NPY-immunopositive neurons was 
counted in each brain region under 20fold magnification. Cell densities and mean 
values were calculated for each animal.  
 
Functional studies: Electroencephalogram (EEG) measurement after 
intracerebroventricular (icv) application of BDNF 
Adult GAERS (n=3) were anesthetized with Narcotane® (0.8-1.0%; Leciva, Praha, 
Czech Republic) and placed in a stereotaxic frame (KOPF® Instruments, Tujunga, 
CA, USA). For cortical EEG recordings, four stainless steel screws (1.5mm diameter) 
were bilaterally placed on the frontal (AP: +2mm) and parietal cortex (AP: -4mm) 
according to the atlas of Paxinos and Watson (1997). Reference and ground 
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electrodes were placed over the cerebellum. A stainless steel icv cannula was 
implanted into the right lateral ventricle (AP: -1.0mm, L: -1.5mm) and lowered to a 
depth of 3.2mm below the dura. Electrodes and cannula were held in place with 
dental cement (SR Triplex® Cold Polymer, Ivoclar Vivadent® Technical, Schaan, 
Liechtenstein).  
EEG was recorded in freely-moving animals 2 to 21 days after the operation. 
Electrical signals were amplified by a Grass 8-10B EEG machine (Grass Instrument 
CO., Quincy, MA, USA). The recording bandwidth was from 0.05 Hz to 10 kHz. 
Analogue to digital conversion was performed using a CED 1401µ type AD converter 
and data captured using the Spike2 software (Cambridge Electronic Design Ltd, 
Cambridge, United Kingdom) at 5 kHz conversion rate. After a 10min habituation, a 
baseline recording was acquired over 60min. 2µl of human recombinant BDNF 
(0.5µg/µl in 0.9% NaCl; Bachem AG, Bubendorf, Switzerland) or vehicle (0.9% NaCl) 
were then slowly (within 2min) injected into the lateral ventricle using a hand-held 
Hamilton syringe (Microliter™ Syringe, Hamilton, Bonaduz, Switzerland). A post-
injection EEG was recorded for 120min. Subsequent treatments were performed at 
the same time point at following days. Additional control experiments were performed 
by only handling the animal. 
SWDs were detected visually in the EEG before and after injection. Criteria for SWDs 
were high-amplitude asymmetric synchronized spikes and slow waves with an 
amplitude of at least 3 times higher than the EEG delta wave activity, a frequency of 
7-11Hz and a duration longer than 1s (Dedeurwaerdere et al., 2005). Begin and end 
of each SWD were manually marked and the duration was measured. All high 
voltage activities shorter than 1s were excluded. Percentage of total duration of 
seizures for each 30min interval was evaluated. The results were expressed as mean 
difference from the vehicle injection ± standard deviation (SD).  
After performing the functional studies, rats were deeply anesthetized with urethane 
(1.4g/kg) and perfused intracardially with physiological saline and 4% 
paraformaldehyde. The cannula tract was visualized by means of the Gallyas silver 
staining method (Gallyas et al., 1993). 
 
Statistics 
Results were subjected to statistical analysis using Student’s t-test. Differences were 
considered to be statistically significant at p-values <0.05 (*) and highly significant at 
p-values <0.01 (**). Western blot and qRT-PCR experiments were performed with a 
total of 10 NEC and 10 GAERS and repeated 3 times. Immunohistochemical 
analyses were accomplished with 6 pairs of juvenile and 3 pairs of adult rats. The 
value for each brain region of control animals was set equal to 100% and appropriate 
values of GAERS were calculated relative to it. Functional studies were performed in 
3 adult rats.  
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Results 
 
BDNF mRNA and protein levels are increased in GAERS 
In juvenile GAERS, BDNF mRNA expression is highly elevated in cortex (160%; 
p<0.01) and in hippocampus (212%; p<0.01; Fig. 2A) as compared to age-matched 
NEC, while in adult GAERS differences in BDNF mRNA expression are less 
pronounced displaying significant higher levels up to 140% (p<0.01) predominantly in 
cortex (Fig. 2B). Differences in BDNF mRNA expression are absent in hippocampus 
of adult animals (Fig. 2B) and in thalamus of both, juvenile and adult GAERS (Figs. 
2A, 2B).  
 
 
 
 
Figure 2. BDNF mRNA levels in cortex, hippocampus and thalamus of juvenile 
(A) and adult (B) GAERS as compared to age-matched NEC using qRT-PCR 
analyses. Dashed line indicates level in the respective region of NEC set at 100%. 
Data show the mean ± SD. PCR runs were performed in quadruplicates and 
repeated three times per sample for 10 animals each (**p<0.01). 
 
 
Quite in contrast, cortical BDNF protein levels are significantly lower in juvenile 
GAERS (72%; p<0.01) as compared to NEC (Fig. 3A, left), whereas in hippocampus 
of juvenile GAERS significantly elevated BDNF levels are found (123%, p<0.01; Fig. 
3A, right). In adult GAERS, increased BDNF levels are detected in both, cortex 
(121%; p<0.01; Fig. 3B, left) as well as hippocampus (119%; p<0.01; Fig. 3B, right) 
as compared to age-matched NEC. No differences in BDNF protein levels are 
observed in thalamus of juvenile or adult GAERS (data not shown).  
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Figure 3. Western blot analysis of cortex (left) and hippocampus (right) 
homogenates derived from juvenile (A) and adult (B) NEC (1-4) and GAERS (5-
8) immunoassayed with BDNF antibody. Quantitative evaluation of BDNF levels is 
shown below. GAPDH immunoreactivity was used for normalization. Data are the 
mean ± SD of 10 animals per group. All assays were run in triplicates (**p<0.01 
compared to age-matched NEC).  
 
 
The precursor form of BDNF (proBDNF) may itself have an independent biological 
activity. However, no changes in protein content of proBDNF are found in cortex, 
hippocampus and thalamus of both, juvenile and adult GAERS as compared to age-
matched NEC (data not shown). 
 
TrkB receptor mRNA is decreased in adult GAERS 
Significant differences between juvenile and adult animals are found in BDNF’s high 
affinity receptor TrkB. In adult GAERS TrkB mRNA expression is significantly 
reduced in both, cortex (83%; p<0.01) and hippocampus (69%; p<0.01), whereas no 
significant changes are found in thalamus (Fig. 4). However, in juvenile GAERS no 
significant differences in TrkB expression are detected in all three brain regions 
examined as compared to age-matched NEC (data not shown). 
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Figure 4. Expression levels of TrkB mRNA in cortex, hippocampus and 
thalamus of adult GAERS as compared to levels in age-matched NEC 
measured by qRT-PCR. Dashed line indicates level in the respective region of NEC 
set at 100%. Data show the mean ± SD. PCR runs were performed in quadruplicates 
and repeated twice (n=10; **p<0.01). 
 
 
Western blot analyses of BDNF’s low affinity receptor p75NTR reveal a significantly 
lower level only in cortex of juvenile GAERS (89%, p<0.05) as compared to age-
matched NEC. Differences are neither observed in cortex of adult GAERS nor in 
hippocampus and thalamus of both, juvenile and adult GAERS as compared to NEC 
(data not shown). 
 
Phosphorylation of CREB is reduced in adult GAERS 
Several studies have shown that in neurons CREB phosphorylation follows TrkB 
activation by BDNF. Thus, it is of interest to investigate whether changes in CREB 
activation accompany alterations in receptor expression. CREB phosphorylation was 
examined using Western blot technique. In juvenile GAERS, no differences in the 
phosphorylation rate of CREB (pCREB) are found in cortex and hippocampus as 
compared to age-matched NEC, although total CREB expression is slightly elevated 
in cortex (111%; p<0.05) and hippocampus (131%; p<0.05; data not shown). No 
significant differences in CREB expression and phosphorylation are found in 
thalamus of juvenile GAERS as compared to age-matched NEC (data not shown). 
In contrast to juvenile animals, CREB phosphorylation (pCREB) is markedly lower in 
adult GAERS. Phosphorylation rates are reduced to 49% in cortex, 39% in 
hippocampus and 68% in thalamus of adult GAERS as compared to age-matched 
NEC (p<0.05; Fig. 5). Expression of total CREB does not differ in all three examined 
brain regions between adult GAERS and NEC (data not shown). 
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Figure 5. CREB phosphorylation rate in cortex, hippocampus and thalamus of 
adult GAERS analyzed by Western blot technique using pCREB (Ser133) 
antibody. Quantitative evaluation of CREB phosphorylation is shown below. Total 
CREB protein expression was used for normalization. Data are the mean ± SD of 10 
animals per group. All assays were run in triplicates (*p<0.05 compared to age-
matched NEC). 
 
 
NPY mRNA is increased in cortex and hippocampus of GAERS 
One of the consequences of the activation of the BDNF-TrkB system may be 
increased synthesis of neuropeptides including NPY. Therefore, expression of NPY 
was analyzed in various brain regions of GAERS. NPY mRNA expression is clearly 
higher in GAERS as compared to NEC (Fig. 6). In juvenile GAERS, NPY mRNA 
levels are elevated to 161% in cortex and 227% in hippocampus as compared to 
age-matched NEC (Fig. 6A; p<0.01). Similarly, in adult GAERS NPY mRNA 
expression is increased to 175% in cortex and 189% in hippocampus (Fig. 6B; 
p<0.01). No significant changes are found in thalamus of juvenile and adult animals. 
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Figure 6. NPY mRNA expression in cortex, hippocampus and thalamus of 
juvenile (A) and adult (B) GAERS as compared to appropriate levels in age-
matched NEC. Dashed line indicates level in the respective region of NEC set at 
100%. Data show the mean ± SD. PCR runs were performed in quadruplicates and 
repeated three times (n=10; **p<0.01). 
 
 
BDNF, pCREB and NPY immunohistochemistry 
Morphological investigations were concentrated on frontoparietal cortex, 
hippocampus and thalamus in order to further verify the biochemical results.  
Controversial data about the BDNF distribution in brain were published probably due 
to immunolabelling with different antibodies (Dugich-Djordjevic et al., 1995; Conner et 
al., 1997; Fusco et al., 2003). BDNF distribution found in our experiments is in 
accordance with results of Fusco et al. (2003); it is localized throughout all cortical 
layers and in almost all subpopulations of hippocampal neurons (Fig. 7A). The 
distribution in cortex and hippocampus suggests a predominant localization in the 
cytoplasm of cell bodies and less in fibres or axon terminals. There is a tendency for 
less pronounced staining in adult rats. While no differences in perikaryal BDNF 
expression occur between NEC and GAERS, there is an increased staining of BDNF-
positive nerve fibres in cortex and hippocampus of GAERS which is more common in 
juvenile than in adult animals (Figs. 7A1, 7A2, respectively). Stained nerve fibres 
occur in particular in hippocampal stratum lacunosum-moleculare of CA3.  
Phosphorylation and therefore activation of CREB was investigated because this 
transcription factor might be involved in the NPY induction by BDNF. Staining for 
pCREB is exclusively found in the nuclei of nerve cells (Fig. 7B). pCREB staining in 
adult GAERS is fainter than in NEC. Differences are most pronounced in 
hippocampal CA1 and CA3 region, but are also detectable in DG and thalamus. Only 
in cortex, no clear differences are visible (Fig. 7B).  
In frontoparietal cortex, NPY-immunopositive cells are distributed throughout all 
cortical layers. Density of NPY-positive cells is higher in cortex of GAERS as 
compared to age-matched NEC in juvenile as well as adult animals (Fig. 7C). In 
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hippocampus, density of NPY-positive cells is highest in DG and CA1, whereas fewer 
cells are detected in CA3. In DG, most of NPY-positive neurons are found in the 
hilus, occasionally at the inner margin of the granule cell layer.  
 
 
 
Figure 7. Visualization of BDNF, pCREB and NPY expression differences 
performed with immunohistochemistry. (A) Comparison of BDNF expression in 
cortex and hippocampus of juvenile (1) and adult (2) NEC and GAERS. Differences 
in BDNF expression in cell bodies are barely detectable, whereas in both brain 
regions, more BDNF-immunostained nerve fibres are detected in juvenile and adult 
GAERS compared to age-matched NEC. (B) Phosphorylation of CREB in cortex, 
hippocampus and thalamus of adult NEC and GAERS. A reduction of pCREB 
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immunoreactivity is detectable in all three hippocampal subregions and thalamus of 
adult GAERS as compared to NEC. (C) Immunohistochemistry of NPY-positive cells 
in cortex and dentate gyrus of juvenile (1) and adult (2) NEC and GAERS. The 
number of NPY-positive cells in cortex and DG of GAERS is markedly higher than in 
age-matched NEC. Note the distinct decline in NPY-immunoreactivity with 
maturation. Scale bar represents 0.1mm for cortex, thalamus and dentate gyrus or 
1mm for hippocampus. 
 
 
NPY-immunopositive neurons are more numerous in DG of juvenile GAERS than in 
age-matched NEC (Fig. 7C1). A smaller increase in expression levels is found in DG 
of adult GAERS (Fig. 7C2). Comparison of NPY-staining in juvenile and adult rats 
reveals a prominent reduction of NPY-immunoreactivity with maturation (Fig. 7C, 
Table 1). Density of NPY-immunoreactive neurons is markedly reduced in 
frontoparietal cortex and in all three hippocampal subregions examined of adult 
GAERS as compared to juvenile GAERS. The number of NPY-immunopositive cells 
in adult GAERS is only half of the levels measured in juvenile GAERS (p<0.01 for all 
brain regions; Table 1). 
 
Table 1. Number of NPY-positive cell counts in frontoparietal cortex, DG, CA3 
and CA1 of juvenile and adult GAERS expressed as cells/mm2. The data shown 
are the mean ± SD (n=6 for juvenile and n=3 for adult GAERS; **p< 0.01 compared 
to juvenile GAERS). 
 
 
To investigate whether BDNF, pCREB and NPY are expressed in the same neuron, 
colocalization studies were performed with DAB nickel for the first antigen resulting in 
a purple staining and with DAB without enhancement for the second antigen leading 
to a brown coloration (Fig. 8). 
BDNF-positive neurons (brown) are very common throughout the whole cortical and 
hippocampal structures (see also Fig. 7A), while NPY-positive neurons (purple) are 
very rare. Notably, most of the NPY-expressing cells are also BDNF-immunopositive 
(Fig. 8A; arrowheads) in cortex and hippocampal CA1 and DG regions. Only a few 
NPY-positive cells do not express BDNF (Fig. 8A; arrows).  
Three different colours are visible in double stainings for pCREB and BDNF (Fig. 8B). 
Brown cells express only BDNF (open arrowheads), purple cells are selective for 
pCREB (arrowheads) and a coexpression of pCREB and BDNF occurs in black cells 
(arrows). Less than half of all neurons are positive for both, pCREB and BDNF. 
Remaining neurons stain either only for pCREB or BDNF.   
NPY-positive neurons (purple) in cortex and hippocampus of GAERS express 
generally pCREB (Fig. 8C; arrowheads). This colocalization is even more common 
than the coexpression of NPY and BDNF. Only very few NPY-expressing cells are 
not positive for pCREB (arrows). Taken together, the vast majority of NPY-containing 
neurons also express BDNF and pCREB.  
43 
 
 
 
Figure 8. Colocalization of two proteins in cortex and hippocampal subregions 
of GAERS. (A) In the majority of cases, NPY-positive neurons (purple colour) are 
also expressing BDNF (arrowheads) and only few neurons are present in CA1, DG 
and cortex which express NPY only (arrows). (B) Colocalization of pCREB and BDNF 
occurs in a small percentage of neurons (black colour; arrows). There are many 
neurons which express detectable levels of either only BDNF (brown colour; open 
arrowheads) or pCREB (purple colour; arrowheads). (3) NPY (purple colour) and 
pCREB (brown colour) are mostly colocalized in cortical or hippocampal neurons 
(arrowheads). There are only few neurons that express solely NPY (arrows). Black 
line indicates the distance of 0.1mm. 
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Icv application of BDNF suppresses occurrence of SWDs 
In order to verify whether changes in the BDNF-system are directly linked to the 
occurrence of SWDs, functional studies were performed by icv application of BDNF 
to adult GAERS. The typical morphology of SWDs – asymmetric spikes and slow 
waves with a frequency of 7Hz - is shown in Fig. 9 in a narrow (above) and broad 
(below) range. Icv injection of BDNF markedly reduces SWDs in adult GAERS. 
60min after BDNF injection, the seizure-time is significantly reduced to 35% as 
compared to the seizure incidence after injection of the vehicle only. Occurrence of 
SWDs completely recovers within 120min after injection of BDNF (Fig. 9). 
 
 
 
 
Figure 9. Time course showing the effect of icv injection of BDNF in adult 
GAERS. Injection of BDNF into the lateral ventricle significantly decreases the 
percentage time spent in seizure 1 hour after application. Occurrence of SWDs 
completely recovers within 120min. Dashed line indicates percentage of time spent in 
seizures measured after injection of 0.9% NaCl. Data are the mean difference from 
the vehicle injection ± SD of experiments performed in 3 different adult GAERS 
(**p<0.01). The typical morphology of SWDs is shown in a narrow and broad range. 
 
 
Discussion 
 
This study reveals marked differences in BDNF expression in GAERS as compared 
to NEC indicating that BDNF may contribute to the pathophysiology of absence 
epilepsy. 
 
The BDNF system in GAERS  
Our data show that the BDNF signalling-pathway is altered in GAERS and that 
enhanced neuronal activity in rats with generalized non-convulsive seizures 
(Wallengren et al., 2005) is accompanied by increased BDNF expression. Juvenile 
GAERS express high BDNF levels, i.e. at an age at which SWDs are not yet present. 
BDNF-expression remains increased in adult GAERS. These characteristic high 
levels of the neurotrophin BDNF are found in cortex, but also in hippocampus, a brain 
structure that is primarily not involved in absence seizures. Thus, the BDNF system 
is altered in GAERS, but it may not be exclusively involved in the initiation of absence 
seizures.  
Our results show discrepancies between BDNF protein and mRNA expression levels 
in the cortex of juvenile and in the hippocampus of adult GAERS. It should be 
stressed that there is no evidence for a tight correlation of BDNF protein 
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concentrations and mRNA levels in normal or epileptic brain tissues (Nawa et al., 
1995). Possible reasons for the discrepancy between BDNF mRNA and protein 
expression may be (1), that BDNF synthesis is regulated at a post-transcriptional 
level (Lipshitz & Smibert, 2000) and (2) that BDNF protein is transported from cell 
bodies of central and peripheral neurons to nerve endings and may share 
neurotransmitter-like functions in the brain (Altar et al., 1997; Altar & DiStefano, 
1998; Jacobsen & Mork, 2004). 
Since it was not possible to demonstrate a direct correlation between changes in 
BDNF expression levels and the onset of SWDs, we extended our analyses to BDNF 
receptors. Adult GAERS display significant decreases in TrkB mRNA expression 
both in cortex and hippocampus, whereas no differences were found in juvenile rats. 
It is conceivable that long-time exposure to high levels of BDNF induces a down-
regulation in TrkB expression or phosphorylation resulting in a loss of 
responsiveness to BDNF. This effect has been previously reported in cultured 
hippocampal and cortical neurons and in adult rat brain upon chronic exposure to 
BDNF (Sommerfeld et al., 2000; Xu et al., 2004). Such an adaptive mechanism 
requires time to establish and may not be fully operative in juvenile animals. 
 
CREB and pCREB in GAERS 
In addition to its role as a neurotrophic factor, BDNF has emerged as an important 
signalling molecule for the immature and adult nervous system. Recent studies 
characterizing intracellular signalling pathways have shown that BDNF induces 
activation of transcription factors, including CREB (Finkbeiner et al., 1997; Blanquet 
et al., 2003). CREB phosphorylation in turn regulates the expression of cAMP-
inducible genes including those responsible for the synthesis of various 
neuropeptides, as e.g. NPY (Pandey, 2003; Wand, 2005). These molecular 
interactions are facilitated by the colocalization of these factors in identical neuron 
subpopulations as indicated by our immunohistochemical analysis. pCREB might be 
the molecular link between BDNF and NPY expression. Notably, most of the cortical 
and hippocampal neurons positive for NPY also express pCREB. The coexistence of 
BDNF and pCREB in the same neuron is predominant, but there are also neurons 
that either express detectable levels of only BDNF or only pCREB suggesting that 
also other transcription factors contribute to BDNF effects. 
Interestingly, in adult GAERS the rate of CREB phosphorylation decreases 
dramatically as compared to NEC, whereas in juvenile GAERS CREB 
phosphorylation does not differ from that of age-matched NEC. The reduction of 
pCREB concentrations in adult GAERS coincides with the decrease of TrkB 
expression and the onset of SWDs, pointing to an important role of this transcription 
factor in the initiation and/or propagation of absence seizures. The precise 
relationship between pCREB and non-convulsive epileptic seizures, however, 
remains to be defined. It should be noted that pCREB initiates transcription of a 
variety of other proteins which may also be involved in seizure suppression. 
 
NPY in GAERS 
CREB modulates transcription of genes that encode NPY and its receptors (Chance 
et al., 2000), supporting the notion that NPY expression is regulated by BDNF as well 
as by CREB. NPY functions as a potent endogenous antiepileptic compound in 
temporal lobe epilepsy (Vezzani et al., 1999b) and experimental evidence indicates 
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that it is also implicated in absence seizures (Stroud et al., 2005; Morris et al., 2007). 
Our data show that NPY mRNA expression is significantly higher in cortex as well as 
in hippocampus of juvenile and adult GAERS as compared to age-matched NEC. 
Surprisingly, absence seizures occur in adult GAERS although brain concentrations 
of the endogenous anti-absence factor NPY are higher than in NEC but lower than in 
juvenile animals. It is conceivable that newborn GAERS suffer already from absence 
epilepsy, but that high levels of NPY prevent the occurrence of SWDs. The decrease 
in the number of NPY-expressing neurons in adulthood as shown by our 
immunohistochemical findings (many more NPY-positive cells in hippocampus and 
cortex of juvenile as compared to adult GAERS) would then cause a critical decline in 
the endogenous antiepileptic potential, resulting in the onset of SWDs.  
 
In summary, we hypothesize that juvenile GAERS are protected against SWDs by 
high levels of NPY. The decrease in NPY expression with maturation allows the 
onset of SWDs. This might be influenced upstream by the chronic overexpression of 
BDNF in adult GAERS leading to a reduction in TrkB expression and CREB 
phosphorylation, which in turn results in the marked decrease in the density of NPY-
positive cells during maturation.  
Although BDNF expression is chronically elevated in adult GAERS, 
intracerebroventricular application of BDNF induces a marked reduction of SWDs. 
The time course appears slightly delayed to that observed after icv injection of NPY 
(Stroud et al., 2005; Morris et al., 2007) and strongly suggests that the anti-absence 
effects of BDNF are mediated at least in part via additional factors as, e.g., up-
regulation of NPY expression. This assumption is corroborated by findings of Vezzani 
et al. (1999a) showing similar timing for increases in BDNF and NPY expression after 
acute seizures and Reibel et al. (2000a) reporting increases in NPY expression 
following BDNF-infusion. In addition, our current results indicate that the majority of 
NPY-positive neurons in the frontoparietal cortex and hippocampus contain BDNF. 
As reported before, the distribution of BDNF-immunoreactivity is in good accordance 
with that of NPY (Iritani et al., 2000), but a direct colocalization has not yet been 
proven. Our results are supported by the fact that nitric oxide synthase expressing 
interneurons which are in the majority NPY-positive also contain BDNF (Fusco et al., 
2003). We assume that only BDNF neurons that simultaneously express NPY 
contribute to anticonvulsant effects. 
Furthermore, we hypothesize that after bolus injection the BDNF-signalling cascade 
is distinct from the common mechanism via TrkB and CREB phosphorylation as 
discussed for chronic BDNF effects. Our results support the notion that suppression 
of SWDs after exogenous application of BDNF in adult GAERS is mediated by a 
direct induction of NPY (Fig. 1).  
 
Absence seizures versus temporal lobe epilepsy  
Epidemiological studies in patients have shown that temporal lobe epilepsy and non-
convulsive generalized epilepsies rarely coexist (Koutroumanidis et al., 1999; Sofue 
et al., 2003; Nicolson et al., 2004; Jeha et al., 2006). This has also been observed in 
the GAERS model of absence epilepsy where induction of epileptogenesis by 
amygdala kindling or injection of kainic acid into the amygdaloid nucleus is impaired 
(Eskazan et al., 2002; Gurbanova et al., 2008). The resistance of GAERS against 
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limbic seizures may at least in part be explained by the decreased capacity of the 
BDNF-signalling cascade in adult rats. 
 
In conclusion, this study shows that the BDNF-signalling cascade is dramatically 
impaired in adult GAERS leading to a marked decrease in the expression of the 
endogenous antiepileptic factor NPY. These dramatic changes come along with the 
onset of SWDs. Finally, exogenously applied BDNF markedly reduces the 
occurrence of SWDs in adult GAERS. We assume that this effect is at least partially 
mediated by NPY. 
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Abstract 
 
Various studies have shown that neuropeptide Y (NPY) possesses anticonvulsant 
properties in models of temporal lobe epilepsy. In addition, NPY also suppresses 
spike-and-wave discharges in a genetic model of generalized non-convulsive 
epilepsy (GAERS).   
Here we demonstrate that the density of NPY-expressing cells is increased in cortex 
and hippocampus of both, juvenile and adult GAERS as compared to age-matched 
non-epileptic controls. Additionally, NPY expression is more pronounced in juvenile 
than in adult GAERS, suggesting that occurrence of absence seizures correlates with 
a significant decrease in NPY synthesis. Moreover, the occurrence of spike-and-
wave discharges in adult GAERS is impaired by intracerebroventricular application of 
NPY and a selective Y2 receptor agonist. In juvenile GAERS, onset of absences is 
facilitated by the treatment with specific NPY receptor antagonists.  
These data strongly corroborate the involvement of NPY in the occurrence of 
absence seizures suggesting the NPY-system as a potential therapeutic target. 
 
 
Introduction 
 
Epilepsy remains a major health problem associated with recurrent spontaneous 
seizures and about 30% of the patients with epilepsy are refractory to drug therapy 
(Rang et al., 2007). The probability of intractability largely depends on the type of 
seizures with temporal lobe epilepsy (TLE) having the poorest prognosis of all 
seizure types in adults (Regesta and Tanganelli, 1999). A major obstacle in 
developing new strategies for treatment is that mechanisms of refractoriness are only 
poorly understood.  
Recent studies have shown that the process of epileptogenesis, as induced by 
amygdala kindling (Eskazan et al., 2002) or intra-amygdaloid kainic acid injection 
(Gurbanova et al., 2008) is retarded in Genetic Absence Epilepsy Rats from 
Strasbourg (GAERS). These two studies demonstrate that GAERS, a well validated 
animal models for human absence epilepsy (Depaulis and Van Luijtelaar, 2005), are 
resistant to secondary generalization of focal limbic seizures. In this polygenic model 
(Rudolf et al., 2004) the duration of spike-and-wave discharges (SWDs) correlates 
negatively with kindling rates strongly suggesting an interplay between limbic and 
thalamo-cortical mechanisms (Onat et al., 2007). Kainic acid or kindling models in 
GAERS provide an opportunity for studying the mutual exclusivity of TLE and 
idiopathic generalized epilepsy as observed in the clinical situation (Jeha et al., 2006; 
Koutroumanidis et al., 1999; Nicolson et al., 2004; Sofue et al., 2003). 
Many studies have implicated neuropeptide Y (NPY) in the control of limbic seizures. 
NPY immunoreactivity increases in epileptic animals (Nadler et al., 2007) and kainate 
or kindling induced seizures are reduced and seizure onset markedly delayed in rats 
overexpressing NPY (Richichi et al., 2004; Vezzani et al., 2002), whereas NPY-
deficient mice are more susceptible to seizures (Baraban et al., 1997; Shannon and 
Yang, 2004). Moreover, exogenously applied NPY functions as potent antiepileptic 
compound in kindling and kainate models (Reibel et al., 2003; Woldbye et al., 1997). 
On the other hand, in absence seizures, too, NPY and its receptors play a central 
role (Morris et al., 2007; Stroud et al., 2005). Also, the role of NPY receptor subtypes 
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in seizures is controversial. Benmaamar et al. (2003) found that down-regulation of 
hippocampal Y1 receptors attenuates kindling, while Brill et al. (2007) reported that 
activation of Y1 suppresses thalamic oscillations. In contrast, stimulation of Y2 
receptors is necessary and sufficient to control limbic seizures (El Bahh et al., 2005; 
Nadler et al., 2007; Vezzani and Sperk, 2004). Finally, Y5 receptor agonists may 
constitute a novel group of drugs in antiepileptic therapy (Baraban, 2002; Woldbye et 
al., 1997).  
Goal of this study is to investigate the potential role of NPY and its receptors in 
generalized non-convulsive epilepsy using juvenile and adult GAERS with regard to 
the resistance to secondary generalization of focal limbic seizures. Juvenile GAERS 
express not yet typical SWDs. Short irregular spike-and-wave discharges (SISWDs) 
appear around postnatal day 30 and disclose various shapes with a typical frequency 
of 5-7Hz (Dedeurwaerdere et al., 2005). With increasing age the number of animals 
with typical SWDs gradually increases and reaches 100% at the age of 3 months 
(Vergnes et al., 1986). First, we determined the number of NPY-positive cells of 
juvenile and adult GAERS in several brain regions as compared to age-matched non-
epileptic controls (NEC). We also measured protein levels of Y2 receptors and tested 
whether absence seizures induce hypertrophy of the hilar area. Finally in direct 
functional experiments, we studied the effects of intracerebroventricular (icv) injection 
of NPY receptor agonists and antagonists on SWDs. 
 
 
Materials and Methods 
 
General chemicals used were purchased from Sigma-Aldrich Chemie GmbH (Buchs, 
Switzerland) unless otherwise stated.  
 
Animals 
NEC and GAERS originating from the Strasbourg breeding colony were used for this 
study. The GAERS strain was selected by inbreeding Wistar rats with spontaneously 
occurring electroencephalographic SWDs characteristic for absence seizures 
(Danober et al., 1998). Seizures start to appear within 1 month-old animals, increase 
with age and are present in 100% of the rats after 3 months. NEC were normal 
outbred Wistar rats without spontaneous absence seizures. The experiments were 
performed in juvenile rats aged 26-30 days and in adult rats older than 3 months. To 
avoid influence of cyclic changes in female sex hormones (Veliskova and Velisek, 
2007), only male adult animals were used. Animals were maintained on an ad libitum 
feeding schedule, housed up to five animals in one cage and kept on a 12h on/12h 
off light cycle. They were kept for at least one week on site before being used in 
experiments. All animal tests performed were in accordance with the guidelines of 
the Swiss Federal Veterinary Office. 
 
Quantification of NPY-immunopositive cells by means of immunohistochemistry 
Rats were deeply anesthetized with 0.5 ml (juvenile) or 0.6 ml (adults) Vetanarcol® 
(Veterinaria AG, Zürich, Switzerland; diluted 1:4 in NaCl 0.9%) and subsequently 
perfused through the ascending aorta with physiological saline followed by a 
phosphate buffered solution containing 0.2% glutaraldehyde and 4% 
paraformaldehyde for 10min and 4% paraformaldehyde for another 20min. Serial 
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40µm thick sagittal sections were cut (Microtome HM 650V, Microme GmbH, 
Walldorf, Germany). Free-floating sections were treated with 1% sodium borohydride 
in 0.05M tris buffered saline for 10min and 0.4% Triton X-100 in phosphate buffered 
saline for 90min at room temperature (both Merck, Darmstadt, Germany). 
Immunostaining was performed using a primary antibody against NPY (1:2’000, 
ImmunoStar Inc., Hudson, WI) with the avidin-biotin-immunoperoxidase method. 
Primary antibody was incubated in a blocking solution containing 5% normal goat 
serum (Vector Laboratories Inc., Burlingame, CA) for 72 h at room temperature. 
Incubation with goat anti-rabbit IgG (H&L) Biotin (1:100; Antibodies Incorporated, 
Davis, CA) took place for 2 h and with ABC reagent (ABComplex/HRP, Dako 
Cytomation, Glostrup, Denmark; solutions A and B 1:100 diluted in phosphate 
buffered saline) for 90 min at room temperature. Tissue-bound peroxidase was then 
developed using 0.03% H2O2 and 0.05% diaminobenzidine (Acros Organics, New 
Jersey, NJ) as chromogen resulting in a brown staining. Chromogen reaction was 
initially standardized under a microscope to define the length of incubation resulting 
in optimal cell staining with minimal background. Sections were mounted on 
gelatinized slides, dried overnight at 37°C, completely dehydrated, cleared in xylol 
(Merck, Darmstadt, Germany) and finally coverslipped with Eukitt® quick-hardening 
mounting media.  
NPY-positive neurons were counted in three sections per animal, using similar 
lateralities for all rats. The interface between two sections was 560μm. Brain sections 
were evaluated using a Nikon Eclipse E800 microscope (Nikon AG, Egg, 
Switzerland) interfaced with a ProgRes C14plus camera and pictures taken using the 
image capture software ProgRes Capture Pro 2.5 (Jenoptik, Jena, Germany). The 
three hippocampal subfields dentate gyrus (DG), hippocampal cornu ammonis 
regions 1 and 3 (CA1 and CA3, respectively) as well as the part of the frontoparietal 
cortex directly overlying the hippocampus and striatum were manually encircled and 
areas calculated. The absolute number of NPY-immunopositive neurons was 
counted in each brain region. Cell densities and mean values were calculated for 
each animal.  
 
Measurement of hilar area 
Every 7th section per animal was stained with cresyl violet to obtain a general 
estimate of the status of tissue preservation. Dried brain sections mounted on glass 
slides were incubated at room temperature as follows: 10min in 0.4% acetic acid 
(Merck, Darmstadt, Germany), 10min in cresyl violet solution (0.2% cresyl violet 
acetate, 0.02% sodium acetate-3-hydrate, 0.2% acetic acid, pH 3.5), another 10min 
in 0.4% acetic acid and shortly rinsed with bidistilled water. Then, sections were 
dehydrated for 5 min in 50% and 70% ethanol (Synopharm, Barsbüttel, Germany), 
decolored for 20min in 4% acetic acid in ethanol, followed by 5min in pure ethanol 
and finally cleared in xylol.  
Hilar area of each animal was measured in four different brain slices with similar 
laterality and mean values were calculated. The hilus is a part of DG and represents 
the area within the inner edge of granule cell layer and the lines connecting the tips 
of the two granule cell blades to the end of CA3 pyramidal cell layer. 
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Sectioning of different brain regions for biochemical analyses 
The respiratory centre of animals was paralyzed through saturation with CO2 
(Carbagas, Basel, Switzerland). The brain was removed from the skull, dissected and 
brain regions (thalamus, hippocampus and dorsolateral cortex, comprising mainly the 
sensorimotor cortex) were separated under a dissecting microscope (SZ-PT, 
Olympus, Tokyo, Japan), immediately frozen in liquid nitrogen and stored at -80°C 
until further use. 
 
Y2 receptor protein determination by Western blot analysis 
Individual samples were homogenized by sonication in 500µl, 300µl or 200µl RIPA-
buffer (NaCl 150mM, Nonidet P-40 1%, deoxycholate 0.5%, SDS 0.1%, Tris-HCl 
50mM (pH 8.72), complete EDTA-free protease inhibitor cocktail tablet (Roche 
Diagnostics, Indianapolis, IN), Na4P2O7 20mM, Na3VO4 2mM, NaF 1mM (Merck, 
Darmstadt, Germany)). Afterwards, samples were purified by centrifugation at 
16’000xg for 1min and at 50’000xg for 20min. Protein concentrations in supernatants 
were determined using a Coomassie dye-based assay (BioRad, München, 
Germany). Homogenates containing 50µg of total protein were resolved on 10% Bis-
Tris gels with MOPS running buffer (both from Invitrogen, Carlsbad, CA) by 
electrophoresis at 90V for 2h. Proteins were then transferred to Hybond™-P PVDF 
membranes (Amersham Pharmacia Biotech, Uppsala, Sweden) for 1h at 30V. For 
immunostaining, membranes were blocked at room temperature for 30min in 5% 
skim milk powder in phosphate buffered saline with 0.1% Tween-20 (Acros Organics, 
New Jersey, NJ). Incubation with NPY2R (L-17) primary antibody (Santa Cruz 
Biotechnolgy, Santa Cruz, CA) was performed overnight at 4°C diluted 1:2'000 in 5% 
skim milk powder solution. Anti-glyceraldehyd-3-phosphate dehydrogenase (GAPDH, 
1:10’000, Santa Cruz Biotechnology, Santa Cruz, CA) was used as housekeeping-
protein for normalization of protein loading. After three 5min washes, blots were 
incubated for 1h at room temperature with bovine anti-goat IgG-HRP-conjugated 
secondary antibodies diluted 1:2'000 or goat anti-mouse IgG-HRP 1:10'000 (both 
from Santa Cruz Biotechnology, Santa Cruz, CA) in 5% skim milk powder solution for 
NPY2R and GAPDH, respectively. Signal intensities were determined using a 
chemiluminescence system (Roche Diagnostics, Indianapolis, IN) and light emission 
was absorbed using Kodak Biomax XAR films. Images were captured in a 
MultiImage™ Light Cabinet and quantified with FluorChem 8000 software (both from 
Alpha Innotech Corporation, Randburg, SA). After subtraction of local background, 
pixel values of specific proteins were normalized to GAPDH values for each sample. 
 
Functional studies: Electroencephalogram (EEG) measurement after 
intracerebroventricular (icv) application of NPY, NPY receptor agonists and 
antagonists 
Adult (n=4) and juvenile GAERS (n=6) were anesthetized by inhaling Narcotane® 
(0.8-1.0%; Leciva, Praha, Czech Republic) and placed in a stereotaxic frame (KOPF® 
Instruments, Tujunga, CA). For cortical EEG recordings, four stainless steel screws 
(1.5mm and 0.8mm diameter for adult and juvenile animals, respectively) were 
bilaterally placed on the frontal (AP: +2mm) and parietal cortex (AP: -4mm) according 
to the atlas of Paxinos and Watson (1997). Reference and ground electrodes were 
placed over the cerebellum. A stainless steel icv cannula was implanted into the right 
lateral ventricle (AP: -1.0mm, L: -1.5mm, depth: -3.2mm for adult animals and AP: -
56 
 
0.9mm, L: -0.6mm; depth -3.5mm for juvenile animals). Electrodes and cannula were 
held in place by dental cement (SR Triplex® Cold Polymer, Ivoclar Vivadent® 
Technical, Schaan, Liechtenstein).  
EEG was recorded in freely-moving animals 2 to 21 days after the operation. 
Electrical signals were amplified by a Grass 8-10B EEG machine (Grass Instrument 
CO., Quincy, MA). The recording bandwidth was from 0.05Hz to 10kHz. Analogue to 
digital conversion was performed using a CED 1401µ type AD converter and data 
captured using the Spike2 software (Cambridge Electronic Design Ltd, Cambridge, 
United Kingdom) at 5kHz conversion rate. After 10min habituation, a baseline 
recording was acquired over 60min. 2µl of various drugs were then slowly (within 
2min) injected into the lateral ventricle using a hand-held Hamilton syringe 
(Microliter™ Syringe, Hamilton, Bonaduz, Switzerland). A post-injection EEG was 
recorded for 120min. Subsequent treatments were performed at the same time point 
at following days.  
SWDs and SISWDs were detected visually in the EEG before and after injection. 
Criteria for SWDs in adult GAERS were high-amplitude asymmetric synchronized 
spikes and slow waves with an amplitude of at least 3 times higher than the EEG 
delta wave activity, a frequency of 7-11Hz and a duration longer than 1s. SISWDs 
observed in juvenile animals disclosed variable discharges with spike-and-wave 
aspects. Characteristics are lower amplitude, frequency of 5-7Hz and duration longer 
than 0.5s (Dedeurwaerdere et al., 2005). Start and end of each discharge were 
manually marked and the duration was measured as described (Stroud et al., 2005). 
Percentage of total duration spent in seizure for each 30min interval was evaluated. 
The results were expressed as mean difference from the vehicle injection.  
After performing the functional studies, rats were deeply anesthetized with urethane 
(1.4g/kg) and perfused intracardially with physiological saline and 4% 
paraformaldehyde in phosphate buffer. The cannula tract was visualized by means of 
Gallyas silver staining method (Gallyas et al., 1993). 
 
Drugs injected for functional studies 
In one set of experiments, adult GAERS received 2µl icv injections of NPY 
(Neuropeptide Y (human, rat) trifluoroacetate salt, Bachem AG, Bubendorf, 
Switzerland; 1.5mM in 0.9% NaCl), Y2 receptor agonist (Acetyl-(Leu28,31)-
Neuropeptide Y (24-36), Bachem AG, Bubendorf, Switzerland; 1.5mM in 0.9% NaCl) 
and Y2 receptor antagonist (BIIE0246 formate, Tocris Bioscience, Ellisville, MO; 
10mM in 40% methanol in 0.9% NaCl).  
In a second series of injections, juvenile GAERS (aged 26-50 days) received 2µl of 
Y1 receptor antagonist (BIBP3226, Bachem AG, Bubendorf, Switzerland; 10mM in 
20% dimethylsulfoxide (DMSO) in 0.9% NaCl), Y2 receptor antagonist (BIIE0246) 
and Y5 receptor antagonist (CGP71683 hydrochloride, Tocris Bioscience, Ellisville, 
MO; 10mM in 20% DMSO in 0.9% NaCl).  
After dissolving, drugs were stored in aliquots at -20°C until use. Doses of drugs 
were chosen on the basis of previous studies showing that antagonists provide a 
complete receptor block (Morris et al., 2007; Polidori et al., 2000). 
Injections of 0.9% NaCl, 40% methanol (Reanal, Budapest, Hungary) in 0.9% NaCl, 
20% DMSO in 0.9% NaCl and artificial cerebrospinal fluid (ACSF, Szent Rokus 
Korhaz es Intezmenyei, Budapest, Hungary) as well as handling without injection 
were used as controls. 
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Statistics 
Results were subjected to statistical analysis using Student’s t-test. Differences were 
considered to be statistically significant at p-values <0.05 (*) and highly significant at 
p-values <0.01 (**). Results are expressed as mean values ± standard deviation 
(SD). Immunohistochemical analyses were accomplished with 6 pairs of juvenile and 
3 pairs of adult rats. Western blot experiments were performed with a total of 10 
juvenile and adult NEC and GAERS and repeated 3 times. Functional studies were 
performed in 4 adult and 6 juvenile GAERS.  
Differences in the number of NPY-positive cells per mm2 between the four groups 
(juvenile, adult, NEC, GAERS) were investigated using univariate two-way ANOVA. 
Kolmogorov-Smirnov- and Shapiro-Wilk-tests were utilized to check normal 
distribution of mean values. Normal distribution of error variances was tested using 
Levene-test. 
 
 
Results 
 
To analyze the role of NPY in the onset and maintenance of SWDs, expression of 
NPY is investigated in different brain regions of juvenile and adult GAERS as well as 
NEC by means of immunohistochemistry.  
 
NPY expression in different brain regions 
Immunohistochemical investigations of NPY expression were concentrated on 
different brain regions such as the three hippocampal subregions DG, CA1 and CA3 
as well as on frontoparietal cortex, thalamus and striatum.  
Generally, only few NPY-immunopositive neurons are found in the investigated brain 
areas. Perikarya are stained whereas only few dendrites or axons of the multipolar or 
bipolar neurons are visible. NPY is preferentially expressed in GABAergic 
interneurons with long smooth dendrites. The highest number of NPY-positive 
perikarya is found in basal forebrain (Fig. 2G) showing also the longest dendrites. In 
contrast, only NPY-positive nerve terminals but no perikarya are observed in 
hypothalamus (Fig. 2H). In cortex, NPY-immunopositive cells are distributed 
throughout all cortical layers (Fig. 1B, 2B). In hippocampus, density of NPY-positive 
cells is highest in DG and CA1 in GAERS, whereas fewer cells are detectable in 
CA3. In DG, most of the NPY-positive neurons are found in the hilus or occasionally 
at the inner margin of the granule cell layer (Fig. 1C, 2C). NPY-immunoreactivity is 
low in the vicinity of the pyramidal cell layer in CA3 (Fig. 1D, 2D), whereas in CA1 
most of the NPY-positive neurons are scattered around this layer (Fig. 1E, 2E). In 
thalamus, only the nucleus reticularis thalami (nRT) shows immunoreactivity for NPY 
in some of its GABAergic neurons (Fig. 1G). Intensity of staining is very weak making 
it hard to distinguish NPY-immunopositive cells properly from the background. 
Quantification of NPY-positive cells in this brain area is therefore not feasible. NPY-
positive axons projecting from nRT to the thalamus proper are not traceable with this 
staining method. No other thalamic nuclei are found to contain NPY-positive 
perikarya (Fig. 1H). NPY-immunopositive cells are distributed throughout the whole 
striatum showing clear dendrites traversing the bundles of white matter (Fig. 1F, 2F).  
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Fig. 1. Immunohistochemical analysis of NPY-positive cells in juvenile GAERS 
as compared to age-matched NEC. Number of NPY-positive cells (A) in the brain 
regions cortex (B), DG (C), CA3 (D) and CA1 (E) is highly elevated in juvenile 
GAERS as compared to the appropriate levels in age-matched NEC (**p<0.01). No 
differences are detected in striatum (F). In thalamus, NPY-positive cells are only 
weakly visible in nRT (G), whereas no other thalamic nuclei were found to contain 
NPY-positive perikarya (H). Dashed line in A indicates number of NPY-positive cells 
in the respective region of NEC set at 100%. 
 
 
Density of NPY-positive cells is elevated in the three hippocampal subregions and in 
cortex of juvenile and adult GAERS 
To quantify expression differences between GAERS and NEC, the density of NPY-
positive cells was determined by morphometry. Mean value for each brain region of 
NEC is set equal to 100% and appropriate values of GAERS are calculated relative 
to it. NPY-immunopositive neurons are highly elevated in the three hippocampal 
subregions DG (178%, p<0.01), CA3 (224%, p<0.01) and CA1 (220%, p<0.01) as 
well as in cortex (158%, p<0.01) of juvenile GAERS as compared to age-matched 
NEC. In contrast, no differences in expression levels between GAERS versus NEC 
are found in striatum (Fig.1A).  
In all investigated brain regions, NPY-immunoreactivity is much lower in adult 
animals than in juvenile ones. Nevertheless, levels in adult GAERS are significantly 
higher than in age-matched NEC. Higher numbers in hippocampal subregions are 
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not as pronounced as in juvenile animals but still exhibit increases up to 138% in DG 
(p<0.05), 141% in CA3 (p>0.05) and 164% in CA1 (p<0.05). In cortex, the increase in 
NPY-immunopositive cells (182%, p<0.01) is even more pronounced than in juvenile 
animals. No differences are observed in striatum (Fig. 2A). Absolute cell densities of 
NPY-positive neurons (cells/mm2) are shown in table 1 (mean ± SD).  
 
 
 
Fig. 2. Immunohistochemical analysis of NPY-positive cells in adult GAERS as 
compared to age-matched NEC. Number of NPY-positive cells (A) is strongly 
increased in cortex (B; **p<0.01) and somewhat less in DG (C) and CA1 (E; *p<0.05 
for both) of adult GAERS compared to the appropriate levels in age-matched NEC. 
The slight increase in NPY-immunoreactivity in CA3 (D) is not significantly distinct 
from NEC. No significant differences were found in striatum (F). Highest density of 
NPY-positive perikarya is present in basal forebrain (G), whereas density of NPY-
positive nerve terminals is high in hypothalamus (H). Dashed line in A indicates 
number of NPY-positive cells in the respective region of NEC set to 100%. 
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Table 1. Density of NPY-positive cells in individual brain regions. Number of 
NPY-positive cell counts in cortex, DG, CA3, CA1 and striatum of juvenile and adult 
NEC and GAERS expressed as cells/mm2. Shown are mean ± SD (*p<0.05; **p<0.01 
compared to age-matched NEC; ‡p<0.01 compared to corresponding juvenile 
animals). 
 
 
 
A prominent reduction of NPY-immunoreactivity occurs with maturation and onset of 
SWDs 
As juvenile animals show more frequent staining for NPY, cell densities are 
compared between juvenile and adult GAERS revealing a dramatic decrease in NPY 
expression with maturation. Mean density of NPY-positive cells is set equal to 100% 
for each brain region of juvenile animals. In adult GAERS, NPY-immunopositive cells 
are reduced to 43% in cortex, 21% in DG, 37% in CA3, 34% in CA1 and 61% in 
striatum as compared to juvenile GAERS (p<0.01 for all brain regions; Fig. 3A). A 
significant decrease of NPY-immunoreactivity occurs in all examined brain regions 
with differences only in intensity. Similar data are found by comparing adult with 
juvenile NEC. The number of NPY-positive cells in adult NEC is decreased to 37% in 
cortex, 27% in DG, 59% in CA3, 46% in CA1 and 67% in striatum as compared to 
juvenile NEC (p<0.01 for all brain regions; Fig. 3B). Thus, the decrease with 
maturation only slightly differs between NEC versus GAERS. 
 
Comparison of changes occurring in the area of various brain regions and in the 
absolute number of NPY-positive cells reveals that decreases in cell densities with 
maturation are not only due to enlargement of brain area but rather to a drastic loss 
of NPY-expressing cells (table 2). 
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Fig. 3. Decline in the number of NPY-positive cells with maturation. A, adult 
GAERS express markedly fewer NPY-positive neurons in cortex, DG, CA3, CA1 and 
striatum as compared to the corresponding levels counted in juvenile GAERS, which 
was set to 100% for each brain region (dashed line). B, similar results were found in 
all examined brain regions of adult NEC compared to the appropriate levels in 
juvenile NEC (**p<0.01). 
 
 
Table 2. Changes in area size, number of NPY-positive cells and cell density of 
various brain regions. Four different analyses were performed: (1) juvenile GAERS 
compared to juvenile NEC, (2) adult GAERS compared to adult NEC, (3) adult 
GAERS compared to juvenile GAERS and (4) adult NEC versus (vs.) juvenile NEC. 
Results are expressed as percentages. Reference values were set equal to 100% 
(*p<0.05; **p<0.01). Note that not total cortices were measured but only that part of 
the frontoparietal cortex directly overlying the dorsal hippocampus, i.e. variations in 
this parameter indicate differences in the thickness of the cortex. 
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Two-way univariate ANOVA reveals that the number of NPY-positive cells in cortex 
depends on age (juvenile vs. adult, p<0.01) and disease (NEC vs. GAERS, p<0.01) 
but that the decrease of NPY-immunoreactivity with maturation is independent of the 
disease state of the animal (Fig. 4A and F). In contrast, in all three hippocampal 
subregions the number of NPY-immunopositive cells is highly regulated by disease 
state and age (p<0.01) and additionally, the decline in NPY-immunoreactivity is 
greater in GAERS as compared to NEC (p<0.01 for DG and CA1, p<0.05 for CA3; 
Fig. 4B-D, F). In striatum, changes in the number of NPY-positive cells occur only 
with age (p<0.01), whereas the disease state of the animal does not reveal any 
influence (Fig. 4E-F).  
 
 
 
Fig. 4. ANOVA evaluation of NPY-positive cells in juvenile and adult NEC and 
GAERS. ANOVA for repeated measures revealed a significant effect for age 
(**p<0.01) on the density of NPY-positive cells in all examined brain regions (A-E). 
Differences in NPY-positive cells due to the disease state were found in cortex, DG, 
CA1 and CA3 (A-D, ‡p<0.01 compared to NEC) with exception of striatum (E). The 
interaction between age and disease state influences NPY-immunoreactivity in DG 
and CA1 (??p<0.01; B and D) as well as in CA3 (?p<0.05; C). F, calculated p-values 
for disease, age and the interaction between these two factors in all examined brain 
regions. 
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Hilar area is enlarged in GAERS 
To investigate more precisely differences observed in the area of DG between 
GAERS and NEC, we performed a quantitative measurement of the size of the hilus. 
The hilar area is defined by the inner edge of the granule cell layer and the lines 
connecting them with the beginning of the pyramidal cell layer of Ammon‘s horn (Fig. 
5A). 
Hilar area gradually increases with maturation of rat brain. Mean hilar area in juvenile 
NEC is 0.232mm2 enlarging up to 0.277mm2 in adult NEC (119%, p<0.05, compared 
to juvenile NEC). GAERS exhibit larger hilar areas in both ages: 0.295mm2 in juvenile 
animals and 0.412mm2 in adults (139%, p<0.01, compared to juvenile GAERS) 
resulting in an increase of 127% and 149%, respectively compared to age-matched 
NEC (Fig. 5B and C, p<0.01).   
 
 
 
Fig. 5. Size of the hilar area is increased in juvenile and adult GAERS. A, hilar 
area is defined by the area within the inner edge of the granule cell layer and the 
lines connecting the tips of the two granule cell blades to the end of CA3 pyramidal 
cell layer. B, mean of the measured hilar area in mm2 of juvenile and adult NEC and 
GAERS (**p<0.01 compared to age-matched NEC; †p<0.05 compared to juvenile 
NEC; ‡p<0.01 compared to juvenile GAERS). C, hilar area of juvenile and adult 
GAERS compared to reference areas of age-matched NEC, which was set at 100% 
(dashed line; **p<0.01 compared to age-matched NEC). 
 
 
Y2 receptor protein levels are increased in adult GAERS 
Y2 receptor is suggested as the NPY receptor subtype involved in the process of 
absence seizures (Morris et al., 2007). Its protein levels were measured by means of 
Western blot analysis to estimate whether the signaling pathway of NPY is also 
altered in GAERS. Slight increases of Y2 receptor protein levels are detected in adult 
GAERS, whereas no differences are found in all brain regions of juvenile GAERS 
compared to age-matched NEC. Cortical Y2 receptor levels are elevated to 138% 
(p>0.05; Fig. 6A) and hippocampal levels to 128% (p<0.05; Fig. 6B) in adult GAERS. 
No changes in expression levels are detected in thalamus. 
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Fig. 6. Content of Y2 receptor protein is slightly elevated in adult GAERS. A 
small but not significant increase of the Y2 receptor protein was found in cortex of 
adult GAERS (A; p>0.05), whereas the elevation in hippocampus reached 
significance (B; *p<0.05).  
 
Functional studies  
In order to verify whether changes in the NPY-system are directly linked to the 
occurrence of SWDs, functional studies were performed both in juvenile and adult 
GAERS. Occurrence of SWDs and onset of SISWDs are directly modified by icv 
application of NPY receptor agonists and antagonists. 
 
SISWDs in juvenile GAERS are less pronounced and more variable than the typical 
SWDs in adult GAERS 
All adult GAERS examined exhibit typical and well distinguishable SWDs with high 
amplitude and a frequency of 7Hz (Fig. 7A). Discharges observed in juvenile GAERS 
(around 1 month) do not yet possess all the characteristics. SISWDs are more 
variable with smaller amplitude, shorter duration and a frequency of 5Hz. 
Nevertheless, the spike-and-wave morphology is clearly detectable (Fig. 7B). Two 
juvenile GAERS (aged 36 and 50 days, respectively) displayed SISWDs before the 
injection of the first drug and are therefore omitted for the analysis. 
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Fig. 7. Typical EEG discharges in GAERS. A, SWDs observed in adult GAERS 
with high amplitude and a frequency of 7Hz shown in a narrow (left) and broad range 
(right). B, SISWDs seen in juvenile GAERS are variable with a shorter duration and 
smaller amplitude than typical SWDs displaying a frequency of 5Hz. Electrode 
locations: a, left frontal; b, right frontal; c, left posterior; d, right posterior 
 
 
NPY and a selective Y2 receptor agonist suppress SWDs in adult GAERS 
To verify the inhibitory role of NPY on the occurrence of SWDs, adult GAERS are 
injected with NPY (3nmol, icv). This treatment markedly reduces the occurrence of 
SWDs in adult GAERS. 30min after injection, percentage time spent in seizure is 
reduced to 63% and further lowered to 44% (p<0.05) within 60min compared to 
seizure incidence after injection of 0.9% NaCl. The occurrence of SWDs completely 
recovers within 90min after NPY injection (Fig. 8). 
To check the hypothesis of Morris et al. (2007) that the suppressing effect of NPY is 
primarily mediated through Y2 receptors, adult GAERS were treated with 3nmol of a 
selective Y2 receptor agonist. A clear reduction of SWDs to about 35% of seizure 
incidence following 0.9% NaCl treatment occurs between 30 and 90 minutes after 
injection. A further decrease to 10% is observed 2 hours after treatment (p<0.05). 
Seizure incidence completely recovers within 24 hours after mimicking NPY effects 
on the Y2 receptor (Fig. 8). 
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Fig. 8. NPY and a specific Y2 receptor agonist (Acetyl-(Leu28,31)-Neuropeptide Y 
(24-36)) reduce the occurrence of SWDs in adult GAERS. The percentage time 
spent in seizure is impaired to 63% and 44% 30 and 60 minutes after NPY injection, 
respectively (continuous line, p<0.05). Treatment with the Y2 receptor agonist 
reduces SWDs to about 35% between 30 and 90 minutes and further to 10% 2 hours 
after application of the drug (dashed line, *p<0.05). Seizure occurrence completely 
recovers within 24 hours. 
 
 
Unexpectedly, injection of the Y2 receptor agonist evokes epileptogenic effects in the 
hippocampus. EEGs from 3 out of 4 adult GAERS display typical focal epilepsies with 
an initial flattening of the amplitude followed by an increase in amplitude of spikes 
with a decrease in frequency over time. Occurrence of focal seizures is first observed 
in electrodes ipsilateral to the injection site followed by a rapid spreading to the 
contralateral hemisphere. Morphology of focal seizures differs between animals, 
probably due to differences in the diffusion of the drug from the ventricle to the 
hippocampus. Two animals show epileptic discharges which are typical for stage 1 or 
2 seizures after hippocampal kindling (Fig. 9A). One adult GAERS displays status 
epilepticus as seen after pilocarpine- or kainate-injection (Fig. 9B). Focal epilepsy 
concomitantly occurs with absence seizures (Fig. 9C). No overt motor convulsions 
were observed, but animals showed a very aggressive behavior.  
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Fig. 9. Epileptogenic properties of the specific Y2 receptor agonist (Acetyl-
(Leu28,31)-Neuropeptide Y (24-36)). A, focal seizures which secondarily spread are 
observed on the ipsilateral site (b,d) of two animals after selective activation of Y2 
receptors. Initial flattening of amplitude and decrease of spike frequency over time 
are two hallmarks of focal epilepsy. B, in one animal, icv application of the Y2 
receptor agonist evokes status epilepticus with a spike frequency of 2-3Hz and 
duration longer than 1 hour. C, rarely, focal and absence seizures are concomitantly 
observed. Absence seizures occur on the hemisphere contralateral to the injection 
site (a,c) and focal seizures on the ipsilateral site (b,d). Electrode locations: a, left 
frontal; b, right frontal; c, left posterior; d, right posterior 
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Y2 receptor antagonist is not able to increase the occurrence of SWDs in adult 
GAERS 
To verify whether suppression of remaining NPY effects results in a further increase 
of SWD incidence, adult GAERS are injected with 20nmol BIIE0246, an Y2 receptor 
antagonist. However, this treatment does not change seizure incidence as compared 
to application of its solvent (40% methanol in 0.9% NaCl; data not shown). 
 
Y1 receptor antagonist facilitates the onset of SISWDs in juvenile GAERS 
To elaborate the protective effect of NPY on the occurrence of SWDs in juvenile 
GAERS, these animals were treated with three different NPY receptor antagonists, 
their solvents and controls. At the start of EEG measurement, SISWDs are not yet 
distinguishable in 4 out of 6 juvenile GAERS (aged 25–33 days). In 3 out of these 4 
juvenile GAERS, first clear SISWDs (Fig. 7B) are observed following the injection of 
20nmol of the Y1 receptor antagonist BIBP3226 at the age of 30, 31 and 39 days. 
The onset of SISWDs occurs 24 to 96 hours after injection of the Y1 receptor 
antagonist without any other treatment in between. The fourth animal shows its first 
SISWDs at the age of 33 days, 24 hours after injection of the Y5 receptor antagonist 
(CGP71683) and 120 hours after injection of the Y1 receptor antagonist.    
 
Y2 receptor antagonist increases the occurrence of SISWDs in juvenile GAERS 
Occurrence of SISWDs was investigated 24 hours after injection of the antagonist as 
compared to baseline incidence before treatment. As shown in figure 10, no 
differences in the SISWD incidence are observed after handling of animals without 
injection, application of ACSF, 40% methanol in 0.9% NaCl and 20% DMSO in 0.9% 
NaCl. Furthermore, application of the Y5 receptor antagonist (CGP71683, 20nmol) 
does not interfere with the occurrence of SISWDs, whereas injection of the Y1 
receptor antagonist (BIBP3226, 20nmol) shows a tendency to aggravate seizures. 
Although the mean value of time spent in seizure is increased to 223% as compared 
to baseline, this augmentation does not reach statistical significance due to broad 
interindividual variability. Inhibition of Y2 receptors with 20nmol BIIE0246 results in a 
significant increase of time spent in seizure to 171% as compared to baseline values 
(p<0.01; Fig. 10). Additionally, the incidence of SISWDs after injection of the Y2 
receptor antagonist is also elevated compared to application of its solvent (40% 
methanol in 0.9% NaCl, p<0.05).    
 
Histological examination of brain sections revealed that all cannulae implanted in 
adult GAERS and half of the ones implanted in juvenile GAERS enter the ventricle. In 
the remaining 3 juvenile GAERS, cannulae tip was placed in the corpus callosum 
right above the ventricle. As no clear differences are observed between juvenile 
GAERS, all animals were included in our analyses. 
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Fig. 10. Effects of different NPY receptor antagonists on the occurrence of 
SISWDs 24 hours after treatment. Percentage time in seizure is influenced by the 
icv application of control substances (black bars) or various NPY receptor 
antagonists (white bars) compared to baseline values set at 100% (dashed line). 
Injection of an Y2 receptor antagonist (BIIE0246 formate) increases the percentage 
time in seizure compared to baseline (**p<0.01) as well as compared to its solvent 
(40% methanol in 0.9% NaCl; †p<0.05; n=4).  
 
 
Discussion 
 
The objective of this study was to investigate the role of NPY and its receptors in an 
animal model for absence epilepsy with regard to the resistance to secondary 
generalization of focal limbic seizures. We show that the density of NPY-positive 
neurons is higher in GAERS and undergoes a prominent reduction with maturation. 
Moreover, SWDs in adult GAERS are reduced by icv application of NPY and a 
selective Y2 receptor agonist, while in juvenile GAERS, onset of SISWDs is 
facilitated by treatment with NPY receptor antagonists. 
 
Density of NPY-positive cells in GAERS  
Our data show a robust higher density of NPY-positive cells in cortex and 
hippocampus of juvenile as well as adult GAERS compared to age-matched NEC 
and support our previous results showing an increase in NPY mRNA expression in 
GAERS (Landweer et al., unpublished results). An increase of NPY expression was 
found in hippocampus of another genetic rat model for generalized epilepsy, the 
spontaneously epileptic rats (Sadamatsu et al., 1995). The increase of NPY 
synthesis is already observed in juvenile GAERS indicating that this effect is not the 
consequence of SWDs but rather the result of a genetic alteration in GAERS. Rats 
overexpressing NPY show a reduction in seizure frequency and a remarkable 
decrease in the progression of seizures in different animal models of TLE including a 
rat model of chronic epilepsy (Noe et al., 2008; Vezzani et al., 2002). The anti-
epileptic effects of NPY are also observed in GAERS, although elevation of NPY 
expression is relatively moderate as compared to transgenic rats overexpressing 
NPY. Distinct differences in NPY expression occur also in hippocampus of GAERS, 
in a brain structure primarily not involved in absence seizures. Similarly, in stargazer 
mutant mice an increase of NPY-immunoreactivity occurs only in DG and not in 
neocortex and nRT, two regions involved in spike-wave synchronization (Chafetz et 
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al., 1995). In contrast, no differences were observed in striatum, a brain region that 
may contribute to an endogenous mechanism controlling the maintenance and 
duration of SWDs (Slaght et al., 2004). Our study reveals a marked decrease of 
NPY-positive cells during maturation. The decrease in density of hippocampal NPY 
neurons is more pronounced in GAERS than in NEC. The fact that this reduction 
coincides with the appearance of absence seizures is compatible with an anti-
absence effect of NPY. We assume that newborn GAERS suffer already from 
absence epilepsy, but high levels of NPY prevent the occurrence of discharges. The 
age-dependent decrease in NPY expression allows then the onset of SWDs. On the 
other hand, the blockage of kindling development in adult GAERS is not compatible 
with decreased NPY-levels unless the difference of NPY expression between mature 
GAERS and NEC is still sufficient to protect GAERS from kindling generalization. 
This interpretation is supported by results of Onat et al. (2007) indicating that the rate 
of amygdala kindling correlates negatively with the intensities of SWDs.  
In thalamus, NPY immunoreactivity is low suggesting that thalamic NPY is primarily 
not involved in the initiation of SWDs. Only nRT expresses NPY in its GABAergic 
neurons (Morris, 1989). In contrast, numerous NPY-positive neurons are found in the 
cortex and their number decreases dramatically with age. Expression of typical 
absence seizures is known to arise from an altered interplay between cortex and 
thalamus although the roles played by the components of this circuitry are still 
unclear. Electrophysiological data have identified a specific site of seizure generation 
within the primary somatosensory cortex in GAERS (Polack et al., 2007). Then, 
SWDs rapidly propagate to other cortical areas and related thalamic nuclei.  
 
Increased size of dentate hilus in animals with absence seizures  
Absence seizures cause a robust increase in the size of the hilar region of the 
hippocampal dentate gyrus. This increase is not the consequence of SWDs per se, 
since larger hilar area is already observed in juvenile GAERS before the appearance 
of SWDs. Increments were not only observed between NEC and GAERS but also 
among immature and adult rats suggesting that hilar hypertrophy is both disease- 
and age-dependent. This is the first evidence that generalized non-convulsive 
seizures elicit changes in the hilar area. The increase is of the same order of 
magnitude as observed after recurrent seizure activity induced during kindling 
(Adams et al., 1998). This observation underscores the strong link between 
generalized non-convulsive seizures originating in the corticothalamic loop and focal 
limbic seizures in the hippocampus. 
Mechanisms underlying hilar enlargement are not clear. One possibility is reactive 
gliosis. Dutuit et al. (2000) showed that the increased neuronal activity in GAERS 
induces specific alterations in the expression of glial fibrillary acidic protein, which is 
considered as marker of reactive gliosis, in the cortex and thalamus of these rats. 
However, no change was observed in whole hippocampus and the hilus was not 
specifically investigated. Gliosis has been associated with neuronal loss in focal 
epilepsy and with the sclerosis observed in the foci. However, in GAERS no neuronal 
loss and no decrease in glutamate decarboxylase, which indicates a loss of GABA 
interneurons, were observed in the frontoparietal cortex and thalamus (Sabers et al., 
1996; Spreafico et al., 1993). 
In models of TLE, dentate granule cell excitability is regulated by hilar inhibitory 
interneurons (Buckmaster and Schwartzkroin, 1995; Ratzliff et al., 2004). Under 
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physiological conditions, NPY is expressed in these interneurons with a 
subpopulation especially vulnerable to seizure-induced injury (de Lanerolle et al., 
1989). Loss of inhibitory interneurons contributes to increased dentate granule cell 
excitability (Martin and Sloviter, 2001) and may disrupt the ability of DG to filter 
incoming seizure activity (Heinemann et al., 1992). When the activity propagates into 
hippocampus, it may lead to neuronal injury and intractable seizures (Engel et al., 
1997). A comparable mechanism has not yet been shown in the case of generalized 
absence seizures. 
 
Y2 receptor protein in GAERS 
Despite convergent evidence that NPY operates anti-epileptic, identifying specific 
receptor subtypes underlying this action has proven controversial. Y2 receptors are 
the primary mediators of the anti-epileptic activity in rats (Klapstein and Colmers, 
1997), but evidence for a role of Y5 has emerged from mouse studies (Marsh et al., 
1999). Based on the results of Morris et al. (2007) we concentrated our analysis on 
Y2 receptors. Interestingly, its expression is slightly elevated after the onset of SWDs 
only in adult GAERS, suggesting that changes in Y2 receptor protein may be a 
consequence of absence seizures. In line with our results, delayed hippocampal 
kindling leads to a transient increase of NPY mRNA in limbic structures and Y2 
receptor mRNA in dentate granule cell layer, entorhinal cortex and amygdala leading 
to suppression of hyperexcitability (Kopp et al., 1999). 
 
Pharmacological manipulation of SWDs in adult GAERS 
Occurrence of SWDs in adult GAERS is drastically influenced by activation of NPY 
receptors. Icv application of NPY and a selective Y2 receptor agonist significantly 
diminishes SWDs with a maximum 60 minutes or 2 hours after injection, respectively. 
In our hands, time courses are slightly delayed compared to previous studies 
showing maximal effects between 15 and 45 minutes after treatment (Morris et al., 
2007; Stroud et al., 2005). 
Not NPY infusion itself, but selective activation of its Y2 receptors evokes focal 
seizures in GAERS. Mechanisms of focal and absence epilepsy do not interfere with 
each other as they occur concomitantly, even though the coincidence rarely exists. 
Motor effects of focal seizures are not observed, but treated animals show very 
aggressive behaviors. Therefore, the focus for epileptic discharges probably lies 
within the hippocampus and not the cortex. Selective targeting of NPY receptor 
subtypes seems to be more critical in interference with absence seizures than with 
the neuropeptide itself. Facilitating effects of NPY on limbic seizures have already 
been described in hippocampus, but Y1 receptors have been proposed to mediate 
this action (Vezzani et al., 1999b). Application of a high-affinity GABAB receptor 
antagonist to adult GAERS evokes similar phenomena. Intraperitoneal application of 
low doses reduces SWDs, whereas intracerebral injection induces focal seizures 
(Vergnes et al., 1997). 
Treatment of adult GAERS with a selective Y2 receptor antagonist does not increase 
seizure incidence. These data indicate that the protective effect of endogenous NPY 
on SWD generation is completely abolished in adult GAERS or that other NPY 
receptor subtypes are involved in the anti-absence effect. 
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Interference with SISWDs in juvenile GAERS 
Onset and incidence of SISWDs in juvenile GAERS can be changed by application of 
NPY receptor antagonists. First clear SISWDs are detectable after treatment with the 
Y1 receptor antagonist, whereas blocking of Y2 receptors resulted in elevated 
seizure incidence. Y5 receptor subtypes do not seem to be involved in the generation 
of absence seizures. Occurrence of SISWDs in juvenile GAERS is very susceptible 
to the environment. During long-term EEG recording incidence of SISWDs decreased 
due to diminished vigilance. The effect of treatment was delayed and therefore 
analysis was performed with data collected 24 hours after injection. Our data give 
first evidence that absence seizures can be evoked in juvenile GAERS by blocking 
NPY receptors. Sun et al. (2002) speculate that Y1 receptor activation leads to 
suppression of nRT excitability and therefore cessation of absence epilepsy.  
 
Taken together, high NPY expression protects juvenile GAERS from absence 
seizures. Onset of SISWDs in juvenile GAERS can be elicited by NPY receptor 
antagonists. NPY expression levels decline with maturation allowing the onset of 
SWDs in adult GAERS. Suppression of absence seizures is achieved by NPY 
treatment. Specific receptor subtypes are involved in the anti-absence effect of NPY. 
One of the mechanisms whereby GAERS are resistant to secondary generalization 
of focal limbic seizures may be related to the significant enhancement of NPY 
expression in GAERS compared to NEC. Absence seizure-induced overexpression 
of NPY may constitute an endogenous mechanism that controls hippocampal 
epileptogenesis. Data from the epileptic human hippocampus showing that NPY 
inhibits perforant path-evoked responses (Patrylo et al., 1999) reinforce the future 
strategy for treating epilepsy by specifically interacting with the brain NPY-system. 
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4  Discussion 
 
The aim of this doctoral thesis is to elucidate the mechanisms underlying absence 
seizures. This work reveals marked differences in neurotrophin and neuropeptide 
expression between GAERS and NEC as well as between juvenile and adult GAERS 
indicating that both systems may contribute to the pathophysiology of absence 
seizures (table 3). 
 
Table 3: Summary of the main findings of this thesis. Differences in protein or 
mRNA levels are investigated in cortex, hippocampus and thalamus of juvenile and 
adult GAERS as compared to age-matched NEC. Additionally, effects of icv 
application of various drugs on SWDs are tested. ↑: increase, ↓: decrease, ↔: no 
significant change, empty fields: not done 
 
 
In conclusion, although many aspects are still unknown, experimental evidence 
clearly demonstrates that:  
• The hilar area of the hippocampal dentate gyrus is markedly enlarged in 
juvenile as well as adult GAERS as compared to age-matched NEC. 
• Expression of the convulsant neurotrophin BDNF is altered in GAERS before 
and after the onset of absence seizures. 
• As TrkB expression and CREB phosphorylation are markedly decreased in 
adult GAERS, we may assume that BDNF signaling is impaired in these 
animals. 
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• BDNF, CREB and NPY are expressed in identical neuronal subpopulations 
facilitating molecular interactions. 
• Levels of the endogenous anticonvulsant compound NPY are highly 
increased in juvenile as well as adult GAERS as compared to age-matched 
NEC. 
• A marked decrease in the density of NPY-positive cells occurs during 
maturation and coincides with the onset of absence seizures. 
• Occurrence of SWDs in adult GAERS is reduced by icv application of NPY as 
well as BDNF. 
• In juvenile GAERS, SISWDs are evoked or increased by treatment with 
antagonists against Y1- and Y2-receptors, but not with an antagonist against 
Y5-receptors. 
 
 
4.1  BDNF is able to switch between pro- and anti-
convulsant effects 
Increased levels of the neurotrophin BDNF potentiate glutamatergic transmission and 
increase neuronal activity in brain finally leading to seizures (Kang and Schuman 
1995; Toth 2005). However, epileptic patients do not constantly suffer from seizures. 
Three down-stream signaling effects of BDNF may cause the cessation of epileptic 
activity: (1) TrkB expression is diminished following chronic exposure to BDNF 
leading to an attenuation of BDNF action. (2) BDNF induces the expression of the 
anticonvulsant protein NPY. (3) Continuous exposure to BDNF significantly increases 
GABA-current amplitude in epileptic brain via PLCγ and protein kinase C pathway 
finally inducing an increase in inhibitory activity (Palma, Torchia et al. 2005). 
The BDNF system is markedly altered in GAERS, but it may not be directly involved 
in the initiation of absence seizures. In adult GAERS, BDNF signaling is impaired due 
to marked decreases in TrkB expression and CREB phosphorylation. Therefore, 
adjustment to chronic neurotrophic input results in attenuation of signal transmission 
leading to a loss of responsiveness to BDNF. In line with our results, chronic 
exposure to BDNF markedly reduces protein and mRNA levels of TrkB and ligand-
induced tyrosine phosphorylation in embryonic (Knusel, Gao et al. 1997) as well as 
adult neurons (Frank, Wiegand et al. 1997). This down-regulation might present a 
protective mechanism against potentially damaging levels of growth factors (Frank, 
Ventimiglia et al. 1996). The decline of TrkB expression recovers rapidly after 
termination of trophic factor administration. Nevertheless, functional desensitization 
to BDNF does not obligatory occur despite a clear reduction in TrkB protein (Frank, 
Wiegand et al. 1997). The decrease in TrkB protein may be explained by receptor-
mediated internalization of the ligand or by clearance of the ligand-receptor complex 
by retrograde axonal transport (Frank, Wiegand et al. 1997). A specific amino acid 
sequence in the intracellular part of TrkB is competent for this process (Sommerfeld, 
Schweigreiter et al. 2000). 
The temporal coincidence of decreases in BDNF responsiveness with the onset of 
SWDs suggests an important role for the TrkB/CREB signaling pathway in the 
initiation and/or propagation of absence seizures. 
79 
 
Despite a significant reduction in TrkB signaling and CREB phosphorylation, NPY 
protein and mRNA levels are still elevated in adult GAERS compared to age-
matched NEC. This fact implicates that NPY expression is not solely regulated via 
TrkB/CREB signaling pathway. We assume that besides this conventional track, 
BDNF is also able to directly induce NPY expression. 
A clue is given by the fact that bolus injection of BDNF drastically depletes the 
occurrence of SWDs in adult GAERS despite diminished TrkB and CREB signaling. 
We assume that the anti-absence effect of BDNF is at least in part mediated via its 
direct effect on NPY expression and that only BDNF neurons that simultaneously 
express NPY contribute to the anti-absence effect. A possible way to demonstrate 
this assumption is to test whether coapplication of NPY receptor antagonists 
abrogates the anti-absence effect of BDNF. 
In juvenile GAERS, expression of both, BDNF and NPY, is already increased as 
compared to age-matched NEC although no epileptic activity is yet present at this 
age. Nevertheless, an underlying imbalance between excitation and inhibition may 
already be present leading to changes in protein expression and making the 
immature brain to a dynamically changing structure (for review see Holmes 1997). 
For example, immature hippocampal neurons respond to GABAA-receptor activation 
by a transient Ca2+ influx, which increases BDNF mRNA expression (Berninger, 
Marty et al. 1995). Elevated BDNF levels in turn may induce hippocampal NPY 
synthesis. 
 
4.2  NPY is a potent endogenous anti-absence 
factor acting via Y1 and Y2 receptors  
NPY protein and mRNA concentrations are significantly increased in cortex and 
hippocampus of juvenile as well as adult GAERS as compared to age-matched NEC. 
Accordingly, NPY-immunoreactivity is markedly increased in adult spontaneously 
epileptic rats with absence-like seizures at an age at which animals already display 
seizures (Sadamatsu, Kanai et al. 1995). Additionally, in stargazer mutant mice, 
another model for non-convulsive SWDs, NPY expression is elevated solely after the 
onset of SWDs. Interestingly, aberrant expression is found in dentate granule cells 
which are normally devoid of NPY. The abnormal synaptic activity pattern during 
SWDs seems to be sufficient to induce ectopic NPY expression. But in sharp contrast 
to GAERS, SWDs are also detectable in hippocampus in this mice model (Chafetz, 
Nahm et al. 1995). 
Therefore, GAERS seem to be the only known animal model with generalized 
absence seizures in which immature animals already display changes in NPY 
expression although seizures are not yet present. Taken together, these data 
implicate that increases in NPY contents in adult animals are a consequence of non-
convulsive seizures intended to counteract epileptic activity. The seizure-induced 
overexpression of BDNF and NPY may be a first stage of an endogenous 
mechanism that controls epileptogenesis. Nevertheless, the epileptic process can 
overcome the endogenous protection and seizures may develop (Reibel, Larmet et 
al. 2000a). In line with this hypothesis, NPY is released from nRT neurons during 
electrical stimulation-induced oscillatory thalamocortical activity in non-epileptic rat 
brain slices. NPY release autoregulates the termination of absence seizures by 
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activation of Y1 receptors leading to an enduring suppression of nRT excitability 
(Sun, Bandrowski et al. 2002). Increased synthesis of NPY in juvenile GAERS is not 
a consequence of SWDs but rather a genetic alteration underlying absence seizures. 
An outstanding finding of this thesis is the drastic loss of NPY immunoreactivity 
occurring during maturation. A similar decrease has been observed previously. In the 
early post-natal cortex, about 3% of all neurons are NPY-positive. The number of 
peptide containing neurons then drastically decreases in the second post-natal 
months to 0.5-1% which is not due to neuronal death but merely to a cessation of 
NPY-production. Neurons are still able to produce NPY on demand, as e.g. after 
application of BDNF (Wirth, Patz et al. 2004). Additionally, decreases in NPY-
immunopositive neurons as well as in BDNF concentration and pCREB-
immunoreactivity occur age-dependently in the hippocampus of Fischer 344 rats 
(Hattiangady, Rao et al. 2005). Age-related changes in NPY expression levels are 
depending on strain and sex of the animals investigated. 
The decline in NPY content occurs in both, NEC and GAERS, but is significantly 
more pronounced in hippocampus of GAERS. Decrease of BDNF signaling cannot 
cause this radical changes in NPY expression as also NEC are affected although 
TrkB expression and CREB phosphorylation remain unchanged in these rats. Normal 
maturation seems to generate these alterations. The drastic diminishment in NPY 
expression in GAERS and therewith the critical decline in the endogenous 
antiepileptic potential allows the onset of SWDs. It is conceivable that newborn 
GAERS suffer already from absence epilepsy but that extremely high levels of the 
anticonvulsant neuropeptide NPY prevent the occurrence of SWDs. 
Further evidence that NPY also acts as potent anti-absence agent originates from 
functional studies. Icv application of NPY reduces the occurrence of SWDs in adult 
GAERS without affecting the frequency of the remaining discharges. Therefore, 
Stroud et al. (2005) suggest that NPY does not inhibit nRT, the pacemaker of SWDs, 
but interrupts thalamocortical oscillations via its action on the ventrobasal thalamus 
or cortex. The authors hypothesize that sole activation of the Y2 receptor is sufficient 
for the anti-absence effect of NPY (Morris, Gannan et al. 2007). Our results 
corroborate this hypothesis. Treatment with an agonist specific for Y2 receptors 
mimics the NPY effect. The occurrence of SWDs is already markedly reduced 30 
minutes after application and remains suppressed for the whole 2 hours recorded. 
Unfortunately, this specific agonist exerts epileptogenic effects in the hippocampus 
probably due to diffusion of the drug into this brain region. Support for the additional 
involvement of Y1 receptors derives from functional studies in juvenile GAERS. 
Application of an Y1 receptor antagonist leads to the first-time appearance of 
SISWDs, whereas Y2 receptor antagonists increase the incidence of the discharges. 
Selective blocking of Y5 receptors had no obvious effects on absence seizures 
suggesting that this subtype is not involved in the generalization of absence seizures. 
All these treatments were well tolerated by the experimental animals with no adverse 
behavioral changes. The immature SISWD pattern consists of slow wave train with a 
fundamental frequency significantly lower than in adult animals as comparable with 
the results obtained by Carcak et al. (2008). Development and propagation of 
seizures as well as their EEG features differ considerably between immature and 
mature brain (Holmes 1997). 
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4.3  Mechanisms of focal and generalized absence 
seizures partially exclude each other 
Pharmacological differences between generalized and focal epilepsy exist both in 
humans and in experimental animals. Two classes of anticonvulsant drugs are 
established, those effective against absence attacks and those used to treat other 
epileptic seizures (Giaretta, Avoli et al. 1987). In humans, coexistence of focal 
epilepsy, such as TLE, and idiopathic generalized epilepsy in the same patient is 
very rare with an incidence of about 0.5-1% (Koutroumanidis, Hennessy et al. 1999; 
Nicolson, Chadwick et al. 2004). Febrile seizures and a positive family history are 
frequently observed in patients suffering from both seizure types. The reason for this 
rarity is poorly understood. Prognosis can be good if the disease is treated with an 
appropriate broad-spectrum antiepileptic drug (Regesta and Tanganelli 1999). 
Similar observations are made in animal models for generalized absence seizures. 
Adult GAERS fail to progress beyond stage 2 seizures in the amygdala kindling 
paradigm and afterdischarge duration is markedly shorter than in NEC (Eskazan, 
Onat et al. 2002). During amygdala kindling, thalamic activity in GAERS may 
generate the resistance to secondary generalization of limbic seizures. In WAG/Rij, 
another model for typical absence seizures, rats can be divided into three groups 
according to their susceptibility to amygdala kindling: kindling-resistant, slow-kindled 
and rapid-kindled rats. Basal SWD durations are highest in GAERS, followed by 
kindling-resistant WAG/Rij rats and are significantly different from the durations 
measured in kindled WAG/Rij rats (Onat, Aker et al. 2007). Therefore, the intensity of 
SWDs correlates negatively with the susceptibility to amygdala kindling (Aker, 
Yananli et al. 2006). In accordance with these results, the first convulsive seizure as 
well as the first spontaneous seizure after intra-amygdaloid injection of kainic acid is 
significantly delayed in GAERS as compared to NEC (Gurbanova, Aker et al. 2008). 
Vergnes et al. (2000) tested the susceptibility of GAERS to kainic acid. First seizures 
after low doses of kainic acid are less severe in GAERS with longer latency, shorter 
duration and smaller quantity. In line with these results, status epilepticus occurs 
more frequently in NEC than in GAERS after high doses of kainic acid. 
A maturation study in GAERS reveals that kindling rate in GAERS is slower than in 
NEC for all ages investigated. However, 20 days old GAERS are kindling-prone and 
the resistance against kindling starts at 30 days of age, when first SWDs appear, and 
increases with age. As 20 days old GAERS are already partially protected against 
kindling although no SWDs are present at this age, no causal link exists between 
SWDs themselves and the kindling resistance (Carcak, Aker et al. 2008). The 
inhibitory mechanisms underlying generalized absence seizures seem to have 
antagonistic effects on the kindling process. We hypothesize that the protection 
against limbic seizures in GAERS is at least partly due to increased expression of the 
endogenous antiepileptic peptide NPY in this animal strain. 
 
A similar protection against generalized tonic-clonic seizures is observed in immature 
rats. In contrast to adult rats, it is not possible to induce status epilepticus by 
application of kainic-acid or pilocarpine in pups (Albala, Moshe et al. 1984; 
Cavalheiro, Silva et al. 1987). Additionally, repetitive status epilepticus episodes in 
juvenile rats induce electrographic and behavioral epileptic features but not TLE (dos 
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Santos, Arida et al. 2000). One possible explanation might be that the higher NPY 
concentrations observed in immature rats exert protective effects against limbic 
seizure as suggested for absence epilepsy. 
  
Limbic structures are not involved in the occurrence of SWDs, although they are 
seizure-prone and participate in the generalization of several seizure models. 
Nonetheless, the rare coexistence of focal and generalized seizures provides 
evidence for an interplay between corticothalamic and limbic seizures. Vulnerability 
to seizure activity in any part of the neuronal network seems to be influenced by 
activity everywhere else. Brain regions beyond the thalamocortical network are 
participating in some aspects of absence seizures. The following results confirm this 
hypothesis. Measurement of local cerebral blood flow at early stages of amygdala 
kindling reveals that more brain regions are activated in GAERS as compared to 
NEC. In addition to somatosensory cortex and thalamus, numerous limbic regions 
are activated (Carcak, Ferrandon et al. 2009). Local cerebral metabolic rates of 
glucose stay elevated in adult GAERS even after suppressing SWDs by 
ethosuximide treatment (Nehlig, Vergnes et al. 1993). Although no SWDs are 
recordable in limbic structures, hippocampal circuits become synchronized as 
seizures occur within the thalamocortical loop. When inhibition in the hippocampus is 
diminished, thalamocortical SWDs spread into this brain region leading to atypical 
absence seizures (Velazquez, Huo et al. 2007). Further evidence for a thalamo-
limbic interaction is the observation that simultaneous stimulation of nRT with 
hippocampal kindling counteracts the generalization of seizures. The nucleus 
reuniens is the only thalamic structure with direct projections to the hippocampus. 
nRT stimulation may influence spreading of discharges by inhibiting the neurons of 
this nucleus (Nanobashvili, Chachua et al. 2003).  
In conclusion, these studies implicate a critical role for limbic structures in 
generalized absence seizures, possibly in preventing the spread of hyperactivity to 
the whole brain. 
 
Information from cerebral cortex, thalamic nuclei, amygdala and hippocampus are 
processed to the striatum and transferred to basal ganglia which are involved in the 
control of seizure activity. Propagation and/or the generation of different types of 
seizure activity in animals can be controlled by the substantia nigra pars reticulata 
which contains GABAergic neurons. In GAERS, rhythmic discharges of cortico-
striatal neurons contribute to the propagation of oscillatory cortical activity to basal 
ganglia (Slaght, Paz et al. 2002). Maturation studies reveal that local cerebral 
metabolic rates for glucose are already increased in 21 days old GAERS in four 
limbic structures (entorhinal and piriform cortices, hippocampus and basolateral 
amygdala) where no SWDs are recorded in mature GAERS as well as in structures 
of the nigral inhibitory system (substantia nigra pars reticulata, superior colliculus and 
globus pallidus) (Nehlig, Vergnes et al. 1998a; Nehlig, Vergnes et al. 1998b). Genetic 
mutations appear to be evident first in regions that could participate actively in the 
control of epileptogenesis. The cerebral metabolic activity is already increased when 
the anatomical substrate for absence seizures may still be too immature to generate 
SWDs. Genetic mutations seem to be responsible for these metabolic increases 
which may represent an inhibitory, seizure suppressing mechanism necessary to 
maintain the brain in the interictal state.  
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Based on a case report, Dematteis et al. (2003) speculate that increased activity in 
striatum may facilitate seizure arrest or limit seizure recurrence by inhibiting neurons 
of the substantia nigra pars reticulata. The involvement of the substantia nigra in the 
control of seizures has been proved by several lesions, biochemical and 
pharmacological studies. Bilateral activation of GABAergic transmission within the 
substantia nigra suppresses seizures in very different animal models of generalized 
seizures including the GAERS model or seizures with secondary generalization. 
Therefore, the striato-nigro-tectal pathway seems to play a critical role in seizure 
suppression (for review see Depaulis, Vergnes et al. 1994).  
 
4.4  Memory performance in children and rats 
suffering from absence seizures 
Discussing changes in expression or activation of BDNF and CREB inevitably leads 
to the question how learning and memory are affected. 
General intelligence of children with typical absence seizures is within the normal 
range. Nevertheless, specific problems with attention, visual memory and fine-motor 
fluency are observed. Latter is improved with adequate anti-absence treatment 
(Siren, Kylliainen et al. 2007). Deficits in attention, verbal learning and word fluency 
persist despite well-controlled seizures (Henkin, Sadeh et al. 2005). Reading abilities 
of children with generalized absence seizures appear almost 2 years behind 
expectations based on school grade level. Some of the learning difficulties may be 
related to absences during school time and possible detrimental side effects of 
anticonvulsive medication (Vanasse, Beland et al. 2005). 
In contrast, it has been shown that adult GAERS learn faster than NEC, though 
awareness is impaired during absences. This effect is not diminished by the 
application of GABAB receptor antagonists, although they completely suppress 
absence seizures (Getova, Bowery et al. 1997). Thus, the occurrence of SWDs is not 
directly associated with the superior performance of GAERS. Elevation of BDNF 
expression in GAERS might lead to this enhanced capacity. It has already been 
shown that the improved formation of spatial memory following exposure to an 
enriched environment is associated with an induction of BDNF mRNA expression in 
the pyramidal cells of hippocampal CA1 (Falkenberg, Mohammed et al. 1992). 
Elevated CA1 BDNF mRNA expression is also clearly associated with higher 
memory performance of senescent rats (Schaaf, Workel et al. 2001). A cause for 
better learning might be that BDNF is involved in the maintenance of long-term 
potentiation, possibly via activation of CREB (Alonso, Bekinschtein et al. 2005) or 
increased expression of CREB mRNA (Vaynman, Ying et al. 2003). Protein kinase A 
and CREB are activated in hippocampus during the process of spatial memory 
formation in rats (Mizuno, Yamada et al. 2002). Furthermore, BDNF is able to 
concurrently increase its mRNA levels and TrkB in the mechanism of synaptic 
plasticity (Vaynman, Ying et al. 2003). Learning training causes a time-dependent 
activation of the transcription factor CREB and simultaneous expression of BDNF 
gene in different regions of the forebrain (Ulloor and Datta 2005). BDNF signaling via 
TrkB/PLCγ/CaMK/CREB has been implicated in hippocampal long-term potentiation, 
acting largely independent from the Ras/ERK/RSK signaling pathway (Minichiello, 
Calella et al. 2002). Further support for the involvement of the BDNF signaling 
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cascade is the observation that learning and memory impairments observed during 
senescence are accompanied by considerable declines in BDNF, pCREB and NPY 
levels (Hattiangady, Rao et al. 2005). Moreover, reduced BDNF concentrations are 
found in hippocampus of patients with Alzheimer’s disease (Hock, Heese et al. 2000) 
as well as a decline in NPY-immunoreactive cells (Chan-Palay, Lang et al. 1986). 
In conclusion, elevated BDNF concentrations might at least in part contribute to the 
superior performance in adult GAERS. 
 
4.5  Final conclusion 
Animal models for absence seizures offer a unique opportunity for understanding the 
pathophysiology of epileptogenesis in animals and possibly, by extrapolation, in 
humans. Nevertheless, models show not necessarily the identical pathophysiology as 
human epilepsy, although the EEG and behavioral picture of a model looks similar to 
a clinical seizure type. 
Notwithstanding our work clearly demonstrates the involvement of BDNF and NPY in 
the pathophysiology of absence seizures in GAERS, their role in human absence 
epilepsy has to be established in clinical studies.  
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5  Outlook 
 
Epilepsy remains a major health problem associated with recurrent spontaneous 
seizures. The drug-resistant epilepsies and partially severe adverse reactions are 
two reasons for the need of new potent antiepileptic drugs designed to block the 
process of epileptogenesis. 
For several reasons the choice of anticonvulsant drugs is especially difficult in 
women: (1) Reproductive endocrine disorders, e.g. irregular menstrual cycles, weight 
gain and hirsutism, have been associated with antiepileptic drugs, especially 
valproate. (2) Clearance of oral contraceptive pills is increased by hepatic enzyme-
inducing antiepileptic drugs as phenytoin, carbamazepine, phenobarbital, topiramate 
and oxcarbazepine. (3) Oral contraceptive pills and pregnancy enhance the 
clearance of many antiepileptic drugs. (4) No antiepileptic drug can be considered as 
absolutely safe during pregnancy (French and Pedley 2008). 
Valproate is currently the first-line treatment for generalized seizures. Weight gain 
and teratogenicity are two problematic adverse reactions associated with this drug. 
Valproate is a major antiepileptic drug with a broad spectrum of activity. It is effective 
against absence seizures as well as focal and generalized tonic-clonic seizures. The 
mechanism of action is still not completely clarified. An interesting observation is that 
chronic valproate treatment specifically increases NPY expression in the nRT (Brill, 
Lee et al. 2006). 
 
The results of this thesis suggest the use of BDNF and NPY in the treatment of 
generalized absence seizures.  
Anti-absence therapy with BDNF seems to be difficult because of its ambivalent 
actions in epileptogenesis. On one hand, BDNF is a key mediator of the 
epileptogenic process favoring the development and progression of epilepsy due to 
its excitatory properties. On the other hand, the neurotrophic actions of BDNF may 
prevent neuronal cell damage during seizures and induction of NPY synthesis 
counteracts epileptogenesis. Therefore, a therapeutic use of BDNF presumably will 
be associated with considerable challenges.  
Implementation of NPY in the treatment of absence epilepsy appears to be more 
promising. First successes are achieved with NPY gene therapy against chronic 
spontaneous seizures in rats. Intra-hippocampal injection of a recombinant adeno-
associated viral vector expressing the human NPY gene fourteen weeks after status 
epilepticus significantly reduces spontaneous seizure frequency and symptomatic 
progression of the disease (Noe, Pool et al. 2008). A major challenge will be the 
development of galenic forms which are non-invasively applied and tolerated by 
patients. An important point to keep in mind is the penetration into the brain by 
crossing the blood-brain-barrier of possible drug candidates. Therefore, low 
molecular weight non-peptidergic substances are preferred to NPY-alikes. They 
should be able to cross the blood-brain barrier and stimulate endogenous NPY 
synthesis and release or directly activate or block selectively NPY receptor subtypes.  
The results of this thesis suggest that primarily Y2 and Y1 receptor subtypes are 
involved in the anti-absence effect of NPY. Drugs activating selectively these two 
receptor subtypes may be efficacious and well-tolerated new therapies for 
generalized epilepsies, for which current treatment options are limited. The adverse 
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reaction of weight gain will probably not be a problem, as mean food intake is 
significantly increased by NPY action via Y5 receptor (Morris, Gannan et al. 2007), 
whereas Y2 receptor subtypes are not involved in the orexigenic effects of NPY 
(Silva, Cavadas et al. 2002). 
 
Drugs mimicking NPY represent powerful treatments not only against absence 
epilepsy (this study and Stroud, O'Brien et al. 2005; Morris, Gannan et al. 2007), but 
also against various other epileptic syndromes (Marksteiner and Sperk 1988; 
Smialowska, Bijak et al. 1996; Madsen, Woldbye et al. 1999; Reibel, Benmaamar et 
al. 2003). The wide range of therapeutic use is similar to valproate giving these drugs 
tremendous potential. Once the therapy is well-tolerated and without severe adverse 
reactions, it will be a valid alternative to valproate treatment. 
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7  Appendix 
7.1  Abbreviations 
ACSF artificial cerebrospinal fluid 
BAD Bcl-2 associated death promoter 
BDNF brain-derived neurotrophic factor 
CA hippocampal cornu ammonis 
CaMK calcium/calmodulin-dependent kinase 
cAMP 3’,5’-cyclic adenosine monophosphate 
CRE 3’,5’-cyclic adenosine monophosphate response element 
CREB 3’,5’-cyclic adenosine monophosphate response element binding 
protein 
CT corticothalamic 
Ct threshold cycle 
DAB diaminobenzidine 
DG dentate gyrus 
DMSO dimethylsulfoxide 
EEG electroencephalogram 
EPSPs excitatory postsynaptic potentials 
ERK extracellular signal-regulated kinase 
GABA γ-amino-butyric acid 
GAERS Genetic Absence Epilepsy Rats from Strasbourg 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GIRK G-protein-activated inwardly rectifying potassium 
icv intracerebroventricular 
ILAE International League Against Epilepsy 
IN interneuron 
IP3 inositol 1,4,5-triphosphate 
IPSPs inhibitory postsynaptic potentials 
MAPK mitogen-activated protein kinase 
NEC  non-epileptic controls 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NGF nerve growth factor 
NPY neuropeptide Y 
NPYR neuropeptide Y receptor 
nRT nucleus reticularis thalami 
NT3 neurotrophin-3 
NT4/5 neurotrophin-4/5 
p75NTR neurotrophin receptor p75 
PI3K phosphoinositide 3-kinase 
PKA protein kinase A 
PLCγ phospholipase Cγ 
qRT-PCR quantitative real-time polymerase chain reaction 
RSK ribosomal s6 kinase 
SD standard deviation 
SISWDs short irregular spike-and-wave discharges 
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SWDs spike-and-wave discharges 
TC thalamocortical 
TLE temporal lobe epilepsy 
Trk tropomyosin-related tyrosine kinase receptor 
WAG/Rij Wistar Albino Glaxo/Rijswijk  
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7.2  Poster presentations 
During the time of my doctoral thesis I had the opportunity to present my work to a 
broad audience of experts in neurobiology during a European and American 
congress. Abstract and poster for the respective conventions are given below.  
 
 
7.2.1  6th FENS Forum of European Neuroscience 
 
Geneva, Switzerland, July 12-16, 2008 
 
 
The occurrence of spike-and-wave discharges in young Genetic Absence 
Epilepsy Rats from Strasbourg (GAERS) coincides with a decrease of cortical 
neuropeptide Y levels.  
 
Landweer S1, Otten U1, Kunz D1, Nitsch C2, Boehrer A3 and Bernasconi R1 
 
1 Institute of Physiology, University of Basel 
2 Institute of Anatomy, University of Basel 
3 INSERM U596 Strasbourg 
 
Absence seizures are associated with the abrupt occurrence of bilaterally 
synchronous 3/s spike-and-wave discharges (SWDs) in the EEG over wide cortical 
areas. They arise from an aberration of the interplay between the cortex and 
thalamus. Non-linear association analysis has identified a specific site of seizure 
generation within the peri-oral region of the primary somatosensory cortex (Meeren 
et al. J. Neurosci. 2002, 22, 1480). Molecular and structural mechanisms involved in 
absence epilepsy have not yet been identified, while a genetic component for its 
aetiology has been suggested. We used juvenile and adult GAERS to study the role 
of neuropeptide Y (NPY) in absence seizures. Determination of mRNA levels and 
quantification of NPY-immunoreactive neurons show higher NPY levels in 
sensorimotor cortex of GAERS as compared to age-matched non-epileptic control 
(NEC) rats. There are much more NPY-positive cells in CA1 and dentate gyrus 
regions of GAERS as compared to NEC. In both, cortex and hippocampus, NPY 
expression is more pronounced in juvenile than in adult rats. In contrast, there is no 
difference in expression levels between GAERS versus NEC in striatum and basal 
forebrain. Our results show that occurrence of SWDs correlates with a significant 
decrease of NPY expression suggesting that NPY prevents SWDs. 
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7.2.2  38th Annual Meeting of the Society of Neuroscience 
 
Washington DC, USA, November 15-19, 2008 
 
 
Neuropeptide Y is an endogenous antiepileptic factor against absence 
seizures.  
 
Landweer S.1,3, Otten U.1, Nitsch C.2, Juhasz G.3, Boehrer A.4 and R. Bernasconi1.  
 
1Institute of Physiology, University of Basel, Switzerland 
2Institute of Anatomy, University of Basel, Switzerland 
3ELTE Budapest, Hungary 
4INSERM U 596 Strasbourg, France 
 
Using juvenile and adult male Genetic Absence Epilepsy Rats from Strasbourg 
(GAERS) we investigated the role of brain-derived neurotrophic factor (BDNF) and 
neuropeptide Y (NPY) in generalized non-convulsive epilepsy. Goal of this study was 
to demonstrate the impact of these neuromodulators on the occurrence of spike-and-
wave discharges (SWDs). Expression levels were determined using Western blot 
analyses, real-time polymerase chain reaction and stereological counting of NPY 
immunopositive neurons. Our results indicate that in the somatosensory cortex 
elevated neuronal activity in adult GAERS is accompanied by an increase in BDNF 
protein levels. In contrast, hippocampal BDNF is already elevated in juvenile GAERS 
which do not yet display SWDs. Moreover, we found highly increased NPY mRNA 
expression in the somatosensory cortex and hippocampus of both, juvenile and adult 
GAERS as compared to age-matched non-epileptic control animals (NEC). In 
addition, quantitative immunohistochemical analyses revealed more NPY-positive 
cells in the hippocampal subregions CA1, CA3 and dentate gyrus of GAERS as 
compared to NEC. In both cortex and hippocampus, NPY expression is more 
pronounced in juvenile than in adult animals. NPY-immunopositive neurons were 
absent in the thalamus of either juvenile or adult GAERS and NEC.  
Our results demonstrate that major changes in NPY expression correlate with the 
occurrence of absence seizures in GAERS. Appearance of SWDs associated with a 
significant decrease of NPY expression suggests a protective mechanism for this 
peptide against absence seizures in juvenile GAERS. Furthermore, these results 
support the concept that the primary somatosensory cortex and not the thalamus 
initiates SWDs. Functional studies to identify the NPY receptor subtype/s involved in 
the protection against absence seizures are in progress. 
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